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ABSTRACT
To detect viral infections and tumors , CD8 T lymphocytes monitor cells for the
presence of antigenic peptides bound to MHC class I molecules. The majority of MHC
class I-presented peptides are generated from the cleavage of cellular and viral proteins
by the ubiquitin-proteasome pathway. Many of the oligopeptides produced by this
process are too long to stably bind to MHC class I molecules and require further
trimming for presentation. Cytosolic aminopeptidases such as leucine aminopeptidase
(LAP), which is IFN- inducible , Bleomycin Hydrolase (BH), and puromycin-sensitive
aminopeptidase (PSA) can trim precursor peptides to mature epitopes and have been
thought to play an important role in antigen presentation. To examine the role of these
aminopeptidases in generating MHC class 1 peptides in vivo we generated mice deficient
in LAP or PSA , as well as cell lines deficient in LAP , PSA, or BH. LAP mutant mice
and cells are viable and grow normally, whereas PSA mutant mice are smaller than their
wild-type and heterozygote littermates , are subfertile as adults , and are subviable as
embryos.
The trimming of peptides in LAP-deficient cells is not reduced under basal
conditions or after stimulation with IFN. Similarly, there is no reduction in presentation
of pep tides from precursor or full length antigen constructs or in the overall supply of
peptides from cellular proteins to MHC class I molecules , even after stimulation with
IFN. After viral infection, LAP-deficient mice generate normal CTL responses to seven
VII
epitopes from three different viruses. Similarly, PSA deficient mice and BH deficient
mice generate normal CTL responses to viral epitopes. These data demonstrate that LAP
and PSA are not essel)tial enzymes for generating most MHC class I-presented
peptides and reveal redundancy in the function of cellular aminopeptidases in most cell
types.
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CHAPTER I
INTRODUCTION
MHC class I molecules present peptides to cytotoxic T -lymphocytes (CTLs) that
survey the body for infected or otherwise aberrant cells. CTLs recognize MHC class I
molecules via their T -cell receptor (TCR). Recognition of an MHC class I molecule
containing an agonistic peptide activates CTLs to proliferate and kil the "offending
cell(s). Upon activation, CTLs may also secrete cytokines such as IFNy; a cytokine that
enhances and alters MHC class I presentation in a most cell types.
Peptides bound to MHC class I are derived from intracellular proteins which may
initially be normal full length sequences. They may be degraded because they are
abnormal , e. , mistranslated and/or misfolded polypeptides (DRiPs), or as part of the
turnover of normal proteins. Regardless of the initial form of the antigen, the generation
ofa majority of the class I-presented peptides requires the proteasome. However, the
proteasome generates some peptides that are longer than the 8 , 9 , or 10 residues required
to bind MHC class I molecules , and that must be trimmed by aminopeptidases located in
the cytosol or ER before they can be presented. This trimming of pep tides by
aminopeptidases is the focus of my thesis studies.
The classical MHC class I presentation pathway
The sources of MHC class I peptides
Theoretically, any protein that is degraded by the proteasome can produce
peptides for MHC class I presentation. Proteins from the cytoplasm, the nucleus , the ER
viruses , long-lived proteins , short-lived proteins , and defective ribosomal products
(DRiPs) can all contribute to the MHC class I peptide repertoire.
An unresolved issue is how much each protein source contributes to the resulting
peptide repertoire. Upwards of 30% of MHC class I peptides has been suggested to come
from newly synthesized proteins that are mistranslated and/or misfolded (1). These
Defective Ribosomal Products (DRiPs) do not pass the "quality control" of chaperone
proteins and are shuttled to the proteasome for degradation, thereby generating MHC
class I epitopes (1-3). This conclusion was largely based on radiolabeling of cells (S
Met) under conditions of inhibited or uninhibited proteasomal activity (1). However, this
approach has been contested by recent data which suggests that the observed increase in
radio labeling of newly synthesized proteins after proteasomal inhibition, which supported
the initial DRiP hypothesis , resulted from a lack of intracellular amino acids that would
have been present and used in new protein sythesis under normal proteolytic conditions
(i.e. functional proteasome) (4). This , combined with computational analyses of the
original DRiP data by another group, suggest that DRiPs do not contribute a large portion
ofMHC class I peptides (5).
However, there is other evidence that may support the DRiP hypothesis. Treating
cells with cycloheximide (which blocks translation ofmRNA) has indirectly been shown
to reduce peptide transport into the ER (6). The reduction of peptide transport by
treatment with cycloheximide (CHX) was comparable to the reduction observed upon
treatment with lactacystin (a proteasome inhibitor), suggesting that a large fraction of
peptides transported by TAP into the ER are derived from newly synthesized proteins
with a short half-life (e.g. DRiPs) (6). However, other data suggests that newly
synthesized proteins are largely protected from proteasomal degradation, and that pre-
existing proteins are preferentially degraded as a source of amino acids for new
translation (4).
Using viral proteins as a model, Reits , et al. demonstrated that the inhibition of
RNA-dependent RNA transcription of viral RNA with ribavirin during an influenza
infection of cells results in the measurable reduction of peptide transport into the ER by
TAP within a short amount of time (30 min) (6). This suggests that newly synthesized
viral proteins can be a major contributor to the MHC class I peptide pool, but it does not
differentiate between the contributions of functional short- lived proteins (or peptide
precursors (7)) and non-functional DRiPs.
In an effort to quantitate the contribution of DRiPs to the MHC class I peptide
pool , an inducible Tet-onloff system was used to express LCMV nucleoprotein which has
a long half- life in cells ()o3 days) (8). Presentation of the NP 118 epitope derived from
this protein was measured over time after translation was repressed by the addition of
tetracycline to the culture. Presentation ofNP118 steadily decreased over a period of
three days to levels of negative control cells , suggesting that this peptide is generated
from short-lived translational products of LCMV-NP protein (possibly DRiPs), rather
than long- lived, mature, functional protein (8).
Although this study demonstrates that DRiPs are one source ofMHC class I
peptides , it does not eliminate the possibility that stable long-lived proteins also
contribute to the MHC class I peptide pool. Full- length OVA and galactosidase have
both been loaded into the cytosol of cells, and then degraded into peptides that were
effciently presented to CTLs (9 , 10), which suggests that functional proteins contribute
to the MHC class I peptide pool. By varying the N- terminal residue of full- length gal
the rates of degradation of gal protein and presentation of gal peptides can be altered
(9). This model demonstration of the N-end rule could suggest that the half- life of
intracellular functional proteins is influenced by the residue on the N-terminus. It may
also suggest that short-lived functional proteins contribute more to the peptide pool than
longer- lived proteins , although this possibility has not been experimentally tested.
The intracellular localization of proteins also affects their level of contribution to
the MHC class I peptide pool. Sequence analysis of an array of peptides eluted from
secreted HLA-B*1801 molecules suggests that 53% of presented peptides are derived
from cytoplasmic proteins , 43% are from nuclear proteins , and 18% are derived from
membrane-bound proteins (some proteins can be found in multiple compartments) (11).
These calculations seem reasonable since proteasomes are localized in the cytoplasm and
the nucleus , and proteins in these compartments are the most highly represented. Other
minor amounts of presented peptides (:S8% each) were derived from ribosomes , the ER
the plasma membrane , mitochondria, the nucleolus , chromosomes , and the Golgi (11).
In order to determine if this pattern is also true for other HLA alleles , MHC class
I pep tides in the SYPEITHI database (12) that are known to uniquely bind HLA-A2 were
cross-referenced with an online database containing information on the subcellular
localization of proteins (13). Roughly 1150 unique peptides that bind HLA-A2 were
successfully localized and determined to be from cellular proteins. From this cursory
screen we have determined that, 31 % ofHLA-A2-presented peptides are derived from
cytoplasmic proteins , 37% are from nuclear proteins , and 24% are derived from
membrane-bound proteins (Ian York, personal communication). Other minor
contributors (:S8%) were the ER, and mitochondria. In addition, some cellular
compartments were represented here (albeit at very low levels) that were not represented
in Hickman s study such as peroxisomes , endosomes , lysosome , late endosomes , and
secretory vesicles.
Despite these minor differences , the data from this brief HLA-A2-peptide screen
are in general agreement with Hickman s findings concerning HLA-B*1801. However a
more thorough examination of the array ofMHC class I peptides is required to validate
the idea that cytoplasmic and nuclear proteins contribute the most to the MHC class I
peptide repertoire.
Along with intracellular location, protein abundance can also affect the level of
contribution of pep tides (and peptide precursors) by proteins, since peptides from
overexpressed proteins in tumors have been shown to be presented at higher levels than
in normal tissue (14). The N-terminal residue of intracellular proteins may also influence
the level of contribution of pep tides from proteins (N-end rule), since proteins with a high
rate of turnover would theoretically contribute more peptides than proteins with a long
half-life (9). It is also likely that changes in the rate of protein turnover can account for
changes in the contribution of certain proteins to the peptide pool (15).
However, protein abundance , rate of protein turnover, and intracellular location
are not the only factors that determine whether a peptide is presented by MHC class 
Many proteins contain peptide sequences that could theoretically bind MHC class I
molecules and serve as epitopes, but do not stimulate immune responses even though
some of these theoretical pep tides bind MHC class I with high affnity (16). One
potential explanation for this is that these peptides may never be generated in vivo due to
cleavage sites within the peptide sequence.
Flanking sequences have also been shown to prevent or contribute to the
generation of potential MHC class I peptides or peptide precursors (17- 19). Some highly
immunodominant epitopes require their natural flanking sequences in order to effciently
compete for transport into the ER by TAP (20). In contrast, some epitopes are destroyed
or presented less effciently due to their flanking sequences (19-21). In fact, by
substituting the flanking sequences of an immunodominant epitope with those of a
subdominant epitope, presentation of the immunodominant epitope is reduced (19).
These data demonstrate that the amino acids around potential epitopes can influence the
presentation of that peptide.
Intracellular proteins are degraded by the ubiquitin-proteasome
pathway to generate MHC class I-presented peptides and peptide
precursors
Most proteins that have reached the extent of their lifespan are polyubiquitinated
by enzymes in the ubiquitin conjugation system (22). In most eukaryotic cells, there is a
single El ubiquitin-activating enzyme , which forms a thiol-ester bond with ubiquitin
(using ATP for energy) activating the C-terminus of ubi quit in for nucleophilic attack.
Then one of roughly twenty (identified) E2 conjugating enzymes transfers the activated
ubiquitin to one of possibly thousands of E3 ligases. The E3 ligase covalently attaches to
the 76-amino acid ubiquitin molecule to lysine residues within the protein (or an already
ligated ubiquitin). They do so by ligating the C-terminus of ubiquitin to the g-amino
group of the side chain of the lysine residue , although there have been reports of
ubiquitin being conjugated to residues other than lysine by viral E3 ligases (23).
Substrates marked with polyubiquitin chains are selectively targeted to the proteasome
for destruction, however not all proteins require polyubiquitination in order to be
degraded by the proteasome (24-26).
Although there are multiple forms of biologically-active proteasome complexes
the 26S proteasome is generally considered to be the most abundant under normal
cellular conditions , and is composed of a 20S core with one 19S cap on each end of the
core. The core contains four stacked rings (two a , and two ~) with seven subunits per
nng. Due to nuclear localization sequences (NLS) in the a rings , proteasomes can be
found both in the cytosol and in the nucleus (27 , 28).
There are six catalytic sites residing in the two inner ~-rings. Two of these sites
are chymotrypsin-like , two are trypsin- like , and two have post-acidic cleaving activity
(27 , 29). However, replacement of some of the proteolytically active subunits with other
subunits (such as those described below) can alter the catalytic activity of the proteasome
and thereby alter the peptide profie of the proteasomal products.
The proteasome degrades proteins into peptides that generally range from 3 to 25
amino acids (30). Some MHC class I molecules can bind 8mers , others 9mers or 10mers
(31-34). Although the proteasome can generate peptides that are 8 to 10 amino acids
long (35), only around 15% of proteasomal products fall within this size range , and most
(around 66%) are shorter (36) and can not stably bind to MHC class I molecules. Studies
with purified proteasomes (37), and in living cells (35 , 37 , 38) have shown that inhibition
of pro tea somal activity results in a loss ofMHC class I peptide generation from full-
length proteins. In addition, inhibiting the proteasome also blocks the generation of
MHC class I peptides from peptide precursors with C-terminal extensions , suggesting
that the proteasome is required for the generation of the proper C-terminus ofMHC class
I peptides (35 , 39).
The enzymatic activity of the immunoproteasome differs from
the proteasome
Extended incubation with IFNy induces the expression of the ~-ring subunits
LMP2 (~1 i), LMP7 (~5i), and MECLI (~2i) which are incorporated into newly
assembling proteasomes (29). Like their constitutively-expressed homologs, these three
subunits are catalytically active. LMP2 replaces ~ 1 (8 or subunit V), LMP7 replaces ~5
(g or subunit X), and MECL- l replaces ~2 (subunit Z) (29 , 40-42). The newly formed
immunoproteasome is different in enzymatic activity from the original proteasome. For
example , LMP7 can enhance cleavages after hydrophobic and basic residues (43), and
LMP2 can enhance cleavage after basic residues , and decrease cleavages after acidic
residues (27 , 43). Such cleavages generate more peptides with hydrophobic and basic
residues at the C- terminus , which is preferred by the TAP transporter for transport to the
, and are essential for binding to MHC class I molecules (29).
With its different sequence preferences and its dependence on IFN for expression
the immunoproteasome has been suggested to be more suited for generating peptides for
antigen presentation. This has been supported by evidence that LMP2-deficient mice
have a decreased ability to present antigen to CTLs for positive selection, and for
stimulation during viral infection (44 , 45). In addition, the immunodominance hierarchy
of flu epitopes is changed in LMP2-deficient mice (45) suggesting that LMP2 may be
involved in generating specific epitopes.
LMP-7 deficient mice exhibit normal numbers of Band T cells , but MHC class I
levels on all subpopulations of lymphocytes in these animals is reduced by 25 to 45%
(46). Exogenous addition of peptide ameliorates this reduction suggesting that LMP7 is
involved in the generation of MHC class I peptides.
LMP2 and LMP7 have been suggested to contribute to the low level of
presentation of one LCMV epitope (47). However, a second study reports that the CTL
response of this epitope is not altered in LMP-deficient mice during a bon a fide LCMV
infection, and further reports that these immunoproteasome subunits are not necessary for
clearance of LCMV (48). These data suggest that although these proteasomal subunits
may be better suited for antigen presentation than those that are constitutively expressed
they are not essential.
Although data on the MECL- l deficient mouse generated by Michael Basler and
. colleagues is as yet unpublished, it has been reported that MECL- l deficient mice have
20% less CTLs than wild-type (49). More information on these mice will no doubt be
forthcoming.
But is the immunoproteasome really better at generating MHC class I peptides?
As mentioned earlier, immunoproteasomes generate peptides with hydrophobic C-
termini, which have higher affnity for the TAP transporter and for MHC class I binding
grooves. Yet more importantly than generating more (or better-binding) MHC class I
peptide ligands , the immunoproteasome may generate more peptides with N-terminal
extensions , which can be trimmed to size by other peptidases within the cell (50). In
order to compare the ability of immunoproteasome and 26S constitutive proteasome to
generate antigenic peptides or peptide precursors , degradation products from in vitro
digests of denatured ovalbumin from each proteasome were analyzed by immunoaffnity
chromatography using a 11onoclonal antibody that recognizes SIINFEKL at the C-
terminus of pep tides , regardless of the N-terminal extension (50). Through chemical
modification, these SIINFEKL-containing peptides could then be quantified.
Immunoproteasomes did not generate peptides faster, more effciently, or of different
mean lengths (50). They also did not generate more SIINFEKL peptide , however the
cleavage pattern of immunoproteasomes was different such that more N-terminally
extended SIINFEKL peptides were generated by the immunoproteasome than by the
constitutive proteasome (50).
It is possible that these peptides can be fUliher trimmed in vivo to produce MHC
class 1 peptides (50). Thus , while the immunoproteasome may not generate more
antigenic peptides directly, they may generate more peptide precursors , which can be
trimmed by aminopeptidases. Therefore , immunoproteasomes may indirectly contribute
more to the MHC class I peptide pool than constitutive proteasomes , although it should
be noted that both proteasomes generate MHC class I peptide precursors (50).
MHC class I peptide precursors can be trimmed by
aminopeptidases
Many epitopes are generated by the proteasome as precursors with the correct C-
terminus , but with additional residues on the N-terminus which need to be removed in
order to bind MHC class I molecules (29 52). In vitro experiments using
soluble cell extracts that were cleared of proteasomes by ultracentrifugation and then
treated with proteasome inhibitors have shown that there are enzymatic activities in the
cell that can trim residues from the N-terminus , but not the C-terminus of peptide
precursors (53). Treating live cells with a variety of pro tea some inhibitors and then
measuring epitope generation (via HPLC or CTL assay) from synthetic N-extended
precursors , or precursors expressed from mini-genes demonstrated that enzymes other
than the proteasome can generate peptides of the correct length. In one study, precursors
with N-extensions of up to 25 residues were presented after proteasomal inhibition (39),
suggesting that MHC class I epitopes can be generated from N-extended proteasomal
products. However, inhibiting the proteasome blocked generation of a mature epitope
from any C-terminally extended precursor, indicating that the proteasome is required for
generating the correct C- terminus (39 , 51).
Together these data suggest that although the proteasome may generate a large
portion ofMHC class I peptides , there are cellular enzymes that can further trim peptide
precursors to produce suitable peptides for MHC class I binding. Aminopeptidases are
characterized by their ability to trim N-terminal residues off peptides. In live cells , N-
extended pep tides with a blocked N-terminus are not trimmed and are not presented by
MHC class suggesting that aminopeptidases can generate MHC class I peptides from
N-extended precursors (28 , 51 , 54).
Pharmacological inhibitors of aminopeptidases have also been used to
demonstrate that aminopeptidases are involved in trimming peptide precursors. Bestatin
is a common aminopeptidase inhibitor (55-59) that, when added to cytosolic extracts
partially inhibits the peptide trimming activity that generates MHC class I peptides (51
53).
Amino acid-conjugated chloromethylketone , AAF-CMK (Ala-Ala-Phe-CMK) is
an inhibitor that has been used in cell extracts to inhibit the trimming of synthetic peptide
precursors (60 , 61). It has also been shown to inhibit the presentation of epitopes to
CTLs generated from full-length tumorigenic protein (RUl) (61), full-length viral protein
(VSV-NP) (60), and certain flu epitopes (62). AAF-CMK also inhibits presentation of
SIINFEKL in cells stably transfected with a full-length OVA construct (60).
However, AAF-CMK is not specific for any single aminopeptidase since it has
been shown to inhibit three cytosolic aminopeptidases (TPPII, PSA, and BH) (60 , 62
63), and may inhibit others. Therefore , it is possible that other aminopeptidases
responsible for trimming in live cells were inhibited by AAF-CMK in these studies. An
additional caveat in these studies is that although AAF-CMK was shown to inhibit the
presentation ofMHC class I epitopes to CTL by live cells (60 , 61), this lack of
presentation was not directly linked to the ability of the AAF-CMK to prevent peptide
trimming (i.e. increase in peptide half-life or peptide concentration). Therefore , the use
of AAF-CMK (and other inhibitors) may affect other cell processes and/or enzymes that
were not examined in these studies.
Butabindide is an inhibitor that has been suggested to be highly specific for TPPII
(64), and has been used to study this enzyme in celllysates (61) and in living cells (54
62). However, butabindide does inhibit other peptidases , e.g. TPPI (65), and the initial
(and subsequent) claims for TPPII-specificity have not examined potential effects of
butabindide on other aminopeptidases, particularly BH, PSA, and LAP.
In total , the studies using pharmacological inhibitors suggest that a few specific
aminopeptidases can trim, generate, and/or destroy many MHC class I peptides.
However, because evidence demonstrating inhibitor specificity is scarce, a more accurate
conclusion from these studies is that aminopeptidases are involved in trimming MHC
class I peptides.
Peptide trimming can occur in the cytosol
Because there are aminopeptidase activities present in the cytoplasm and the ER
an impOliant question is how much do the activities from each compartment contribute to
producing MHC class I peptides. At least one peptide (RUl) has been shown to be
trimmed exclusively in the cytosolic fraction of cell lysate , and not by ER luminal
proteins or ER-membrane proteins (61). This indicates that cytosolic aminopeptidases
may be required for the presentation of at least some peptides. Other studies have also
used cytosolic celllysates and purified cytosolic aminopeptidases to demonstrate that
cytosolic aminopeptidases can trim MHC class I peptides (51 61). These
biochemical studies demonstrate that cytosolic aminopeptidases can trim peptides , but
they do not show that this is what occurs in vivo.
In living cells , TAP does not effciently transport long peptides ()o25AA) into the
ER (66 67). Therefore , peptide precursors of this length would likely require trimming
in the cytosol prior to transport. Indeed, peptides from precursors of this length have
been shown to be effciently presented by MHC class I (39), suggesting that cytosolic
aminopeptidases can trim proteasomal products of this size. In addition, the half-life of
microinjected peptides in the cytosol ofliving cells has been related to the activity of
aminopeptidases in the cytoplasm (28 , 54). Overexpression of LAP (a cytosolic
aminopeptidase) results in the reduced half- life of endogenous peptides (28) and the
reduced MHC class I presentation of certain epitopes (68). In contrast, peptide half-life
in the cytoplasm is increased when the N-terminus of the peptide is blocked (28).
Together, these data suggest that cytosolic aminopeptidases can trim MHC class I
peptides in vivo.
MHC class I peptides can be trimmed by leucine
aminopeptidase in the cytosol
Leucine aminopeptidase (EC 3.4. 11. 1) (LAP3 in humans) was one of the first
aminopeptidases to be implicated in antigen processing. It is a Zn2+ -binding
metalloprotease which was described in 1964 when it was isolated from swine kidney
(69), but may have been discovered even earlier (70 , 71). LAP has a number of other
names such as cytosol aminopeptidase , leucyl aminopeptidase (72), and peptidase S (73).
LAP levels in blood have been used as a diagnosis of breast cancer (74), and liver
damage (75). It has also been implicated in the catabolism of glutathione (the main
cellular defense against oxidative stress) (72 , 76). LAP is susceptible to bestatin (53), as
are many aminopeptidases (55 , 58 , 77).
LAP was identified as a major enzymatic activity in cytosolic extracts from HeLa
cells that was capable of trimming N -extended precursors of SIINFEKL , an antigenic
peptide from OVA , to the mature presented epitope (53). And as previously mentioned
overexpressing LAP in cells leads to more rapid trimming of pep tides (28) and a
reduction in peptides available for binding MHC class I molecules (28 , 68). These data
suggested that LAP played a major role in trimming peptides for presentation by MHC
class 1. This may be particularly true during an immune response (such as during a viral
infection) since the LAP gene is strongly upregulated both by type I (78), and type II IFN
(53 , 79).
MHC class I peptides can be trimmed by Puromycin-sensitive
aminopeptidase and bleomycin hydrolase in the cytosol
PSA (EC 3.4. 11.14), also known as MP 100 or NPEPPS , is a Zn2+ -binding
metalloprotease that was initially identified in 1981 (80) It is a highly conserved protein
sharing 98% identity between human and mouse (81), and is considered to be a
housekeeping gene due to the high GC content and multiple Spl-binding sites in its gene
promoter region (81). . The protein is mainly cytoplasmic although one membrane-
associated form has been identified in the brain (82 , 83). It has been suggested to playa
role in Alzheimer s disease progression by generating ~-amyloid peptide (84), although
this has been disputed (85). In addition, PSA has been suggested to be involved in
neuropeptide degradation (86-88), although this has also been questioned since PSA is
mainly an intracellular pr9tein (83), and the expression and distribution ofneuropeptides
in the brains of PSA-deficient mice appears to be normal (89). PSA has also been
suggested to associate with mitotic spindles , perhaps through microtubule binding sites
which are similar to those found in tau protein (58 , 90). This association has been
implied to be important for cell cycle progression (58).
BH (EC 3.4.22.40) is a cysteine protease that has also been conserved through
evolution (92% identity between rabbit and human) with broad tissue expression in
humans (91), and a housekeeping gene structure (92). It derived its name from its ability
to hydrolyze the antitumor agent bleomycin, and has been shown to be upregulated in a
number of bleomycin-resistant tumors and cell lines (91 , 93 , 94). BH can exist as a
homohexamer, making it roughly 300 kDa and barrel-shaped (similar to the proteasome)
(95). It has been argued that a genetic polymorphism in BH is linked to susceptibility to
Alzheimer s disease (96-99), however this is controversial (100- 102).
PSA and BH were both suggested to playa role in MHC class I peptide
processing based on 1) their ability to trim the VSV nucleoprotein epitope (NP52-59) in
soluble cell extracts , 2) their sensitivity to the aminopeptidase inhibitor AAF-CMK
which was shown in living cells to inhibit presentation ofNP52-59 generated from N-
extended precursors , and 3) their resistance to the proteasome inhibitor lactacystin (60).
In this initial study, cells were lysed and the lysates were depleted of proteasomes
and ER-fraction. The soluble cell lysate was separated into fractions by column
chromatography. Fractions that cleaved a fluorogenic substrate and were sensitive to the
aminopeptidase inhibitor AAF -CMK were fUliher purified. Then, after running these
purified fractions on a polyacrylamide gel , in-gel digests and mass spectrometry revealed
that two major bands in the active fractions were PSA and BH. Stoltze then showed that
purified BH and PSA could trim precursors of the VSV-NP epitope , suggesting that these
aminopeptidases are important for peptide processing (60). This study went further to
demonstrate that pre-incubation ofliving cells with AAF-CMK could prevent MHC class
I presentation of the VSV epitope (and SIINFEKL) in cells transfected with peptide
precursors , again suggesting that BH and PSA were involved in the processing of this
precursor.
Although this study was the first to implicate BH and PSA in antigen processing,
it contained a few crucial caveats. First, AAF-CMK was used to detect or inhibit
cytosolic aminopeptidases , however it is possible that AAF-CMK inhibited
aminopeptidases in the ER as well. An experimental control that could have been
included in Stoltze s experiments is the expression of an ER-targeted peptide precursor in
T AP-deficient (or ICP4 7 -expressing) cells that were also treated with AAF -CMK. This
would have evaluated the possibility that an ER-aminopeptidase is responsible for the
observed trimming activity in vivo. A second caveat is that treating the cells with AAF-
CMK may have resulted in a non-specific inhibition of the class I processing pathway.
The authors could have used a construct or recombinant virus that expressed the mature
epitope (requiring no processing) as an appropriate control. Therefore, with these
weaknesses in mind, only a weak correlation can be made between the in vitro peptide
trimming activity of purified PSA and BH, and the in vivo role of these enzymes in
antigen presentation.
To extend the find ngs on PSA, another study using human cells suggested that
PSA could process the RUI epitope in tandem with TPPII, and that PSA was required for
the presentation of this epitope to CTLs (61). In addition, Saric et al has suggested that
PSA degrades the Sendai nucleoprotein epitope (F APGYNP AL) in cell extracts better
than any other peptidase (59). This preferential trimming ofFAPGYNPAL in vitro 
presumably due to the basic and hydrophobic residues in this peptide , which are preferred
by PSA (103).
A further indication that BH may be involved in peptide trimming is that it (like
all cysteine proteases) is susceptible to the cysteine protease inhibitor E- , which was
shown to block presentation of one MCMV epitope from an N-extended precursor
expressed from a recombinant vaccinia mini gene (104). However, E-64 inhibits many
other proteases (105) and it did not inhibit the generation of the NP52-59 epitope in a
different cell line (60). The difference in the ability of E-64 to inhibit antigen generation
in one cell line , but not another may suggest that the role of specific aminopeptidases
may vary in certain cell types , and/or that aminopeptidases prefer some peptide
sequences over others.
TPPII and other aminopeptidases that might be involved in
peptide trimming.
Although I have not included the following aminopeptidases in my studies , it is
important to mention them here due to their potential role in MHC class I peptide
processing. Tripeptidyl peptidase II (TPPII) is a cytosolic aminopeptidase that has been
suggested to have a role in peptide trimming (61 63). TPPII is an enormous protein
complex with a mass of 5000 to 9000 kDa (61). It was originally thought to act similarly
to (and perhaps to substitute for) the proteasome (106- 108). Although later studies
suggested that these findings were due to artifacts (109 , 110), the idea that TPPII can
compensate for reduced proteasome function has recently been revived (62). As its name
implies , TPPII cleaves three residues at a time from the amino-terminus of peptides
however it requires a free N-terminus for this activity (54). It has a slight preference for
hydrophobic residues , but cannot cleave before or after proline residues (110). It also has
been reported to have a poorly characterized endopeptidase activity, however the
physiological relevance of this activity remains to be determined (110).
TPPII has been suggested to act in concert with PSA to trim the RU I peptide for
presentation (61). This study used cytosolic extracts , inhibitors , and purified
aminopeptidases to show that TPPII can trim the first three residues off a 19-mer
precursor of the RUI peptide , while PSA completed the final N-terminal trimming steps.
This preference for longer peptides was also observed by another group that treated living
cells with butabindide followed by microinjection offluorogenic substrates (54). Upon
treatment of butabindide , degradation of peptides longer than 15 residues was no longer
observed, suggesting that an enzyme susceptible to butabindide (presumably TPPII) is
responsible for trimming tJ:ese very long peptide precursors (54). Targeting ofTPPII
with siRNA revealed similar results (54). Based on these data, Reits , et al. suggest a
model whereby proteasomal products that are longer than 15 residues and have the
correct C-terminus , can initially be trimmed by TPPII. These peptides can then be
trimmed by other cytosolic or ER-resident aminopeptidases in order to generate the
proper antigenic peptide (54).
Aside from TPPII and the aminopeptidases that I am studying, there are a number
of other aminopeptidases present in the cytosol. Although these aminopeptidases have
not been reported to be involved in antigen presentation, it is nevertheless important to
recognize them. They include methionine aminopeptidase and methionine
aminopeptidase 2 (EC 3.4.11.18), which prefers (but is not limited to) cleaving N-
terminal methionines , and are thought to be important for cleaving the starting
methionine from nascent proteins (111). Prolyl aminopeptidase (EC 3.4.11.5) prefers N-
terminal prolines (112). Arginyl aminopeptidase, or aminopeptidase B (EC 3.4. 11. 6) can
cleave N-terminal arginines and lysines , and is thought to be involved in multiple
processing mechanisms including spermatozoa formation (113), and may also be secreted
(114). Aspartyl aminopeptidase (EC 3.4. 11.21) can liberate aspartate or glutamate from
peptides , and is thought to be important for cellular protein and peptide metabolism
(115) .
Currently, it is unkown what the relative contribution of each aminopeptidase is
to the total intracellular aminopeptidase activity. Some of the factors that would be key
to determining such roles are cell type (since aminopeptidase expression levels vary
among cell types), the substrate used (since aminopeptidases have amino acid biases),
and culture conditions.
Peptides are transported into the Endoplasmic Reticulum by
TAP
After the cytosolic events of antigen processing, a fraction of the resulting
peptides are transported to the ER lumen via the transporter associated with antigen
processing (TAP). TAP is an A TP-binding cassette (ABC) transporter that specializes in
transporting cytosolic peptides into the ER where they associate with MHC class I
molecules. A functional TAP complex is composed of TAP 1 and T AP2 that form a
heterodimer (116). Tapasin, calreticulin, and ERp57 act as complex
stabilizers/chaperones for the empty MHC class II~2-microglobulin complex that is
associated with TAP (117- 119).
TAP selects peptides in the cytosol generally suitable for binding the species-
specific MHC alleles based on C-terminal residues , but TAP is not very particular to
internal sequences (120). Human TAP prefers peptides with hydrophobic or basic
carboxyl termini (121 , 122), whereas murine TAP prefers hydrophobic C-termini (122).
TAP generally prefers binding peptides that are 8- 16 residues in length (123
124), although it has been suggested that TAP can transport peptides of up to 40 residues
in length, albeit with low yffciency (125). TAP' s preferences for binding have been
suggested to be a major limiting factor in the presentation of certain peptides (7).
If a peptide can bind with suffcient affnity to the TAP complex , an A TP-
dependent reaction transports the peptide through the pore into the ER lumen (126),
where it binds to empty MHC class I molecules held in the peptide-loading complex
(PLC). The PLC is made up of a number of chaperone proteins that aid in retention of
the class I molecule until it binds a peptide. These chaperones include calreticulin
ERp57 , and Tapasin. In mice , calnexin can also be considered part of the PLC , since it
remains associated with the MHC molecule during peptide loading (127 , 128), whereas
calnexin is replaced by calreticulin during MHC class I assembly in human cells (117
129). Calreticulin (CRT) has been shown to associate only with peptide-receptive forms
of MHC class II ~2m complexes (117 , 130), and to dissociate from Tapasin and MHC-
1I~2rnpeptide complex after peptide binding (131), although there may be some data that
conflcts with this model (119). The exact function of calreticulin in the PLC remains
under investigation (119). Tapasin (TPN) acts as a bridge between TAP and MHC class
and is one of the chaperones responsible for retaining MHC in the ER until an
appropriate peptide is bound (119 , 132). TPN has been suggested to serve as a "peptide
editor" by selecting peptides of high affnity for binding empty MHC class I (119 , 133).
Once the peptide is bound in the groove, the MHC class IIpeptide complex is
released from TAP (134 135). If an MHC class I molecule cannot bind a peptide , then it
is eventually retro-translocated to the cytoplasm for proteasomal degradation (136 , 137).
This retro-translocation is thought to occur by way of the Sec61 translocon, and may also
be the means by which unbound peptides make their way back to the cytosol for further
degradation (138).
10 ER-Iocalized aminopeptidases can trim MHC class I peptides
There is a growing body of evidence to suggest that peptides may be trimmed
after transport by TAP , and before (or perhaps during) MHC class I peptide loading. As
mentioned earlier, some immunodominant peptides may require natural flanking
sequences in order to be transported into the ER (20 , 139). The fact that these peptides
cannot be presented with those flanking sequences suggests that they undergo trimming
in the ER after their transport by TAP (7, 20 , 21 , 139). In TAP-deficient cells , large
peptide precursors of influenza nucleoprotein epitope that are targeted to the ER via a
hydrophobic signal sequence can be trimmed to the correct 9-mer as detected by RPLC
and CTL assay (140). A number of other studies have also used peptides preceded by a
signal sequence in order to study ER- localized trimming of pep tides (39 , 141- 143).
In TAP-deficient cells , ER-targeted expression of pep tides composed of two
tandem epitopes results in the presentation of the C-terminal , but not the N-terminal
epitope , suggesting that the N-terminal epitope is destroyed before it can bind MHC class
1(140 , 144 , 145). This trimming activity was localized to the ER, rather than in the late
trans-Golgi or post-Golgi vesicles (144). Together, these data indicate that there are ER-
resident enzymes that can trim MHC class I peptides and peptide precursors.
ER- localized aminopeptidase 1 (ERAPl) is a ubiquitous (146) Zn
metalloprotease that was simultaneously reported by two groups as a major peptide-
trimming activity localizeQ in the ER lumen. One group reported its role in murine cells
(141), while the other reported its role in human cells (142 , 147). Serwold, et al. reported
that reducing mouse ERAP 1 led to a reduction of overall MHC class I presentation and
the presentation of a few specific epitopes , whereas the presentation of other epitopes was
enhanced (141). York et al. reported that reducing human ERAP1 with siRNA decreased
presentation of ER- targeted LEOLESIINFEKL almost completely (142). Therefore
ERAPI may be the only enzyme that can trim N-extended SIINFKEL in the ER. In
contrast to these results, when SIINFEKL was expressed in the cytosol , loss of ERAP 
only reduced antigen presentation by 70-80%. The residual presentation of the cytosolic
precursor indicated that there is some contribution to trimming by cytosolic
aminopeptidases (142).
The findings by York, et al. are in conflict with a recent study, which shows that
the presentation of three ER-targeted precursors in HEK293 cells is only minimally
affected (reduced by 10-30%) by ERAPI knockdown, even after stimulation with IFNy
(148). The presentation from these precursors is further reduced (over 50%) only when
the ERAP1 knockdown cells express the TAP inhibitor ICP47 , suggesting that a TAP-
dependent mechanism, which may involve peptide recycling to the cytoplasm, can
compensate for the loss of ERA PI (143 , 148).
The observation that these ER-targeted peptides are presented in the absence of
ERAPI may conflct with conclusions made by York, et al. (142), however both studies
demonstrate that ERAP 1 can trim pep tides in the ER, and that cytosolic aminopeptidases
can trim peptides to the final epitope independently ofER-localized trimming activity.
Presumably the difference between the York and Saveanu studies relates to the use of
different cell lines. The HeLa cells used by Saveanu express a second ER
aminopeptidase ERAP2 , which can substitute for ERAP 1; this enzyme is absent in mice
and the HeLa cells used by York (1. York, personal communication).
Another point of conflct is the effect of ERAPI on overall MHC class I
presentation. York, et al. reported that knockdown of ERAP 1 in HeLa cells enhances
overall MHC class I presentation, and overexpression of ERAP 1 in COS cells reduces
presentation, suggesting that in humans , ERAP 1 generally destroys potential pep tides
under normal conditions (142). York, et al. further concluded that HeLa cells treated
with IFNy after knockdown of ERA PI presented less MHC class 1 than control cells
suggesting that ERAP 1 may contribute to the peptide pool under these conditions (142).
In contrast, Saveanu, et al. has reported that knockdown of ERAP 1 in HeLa cells
reduces overall presentation ofMHC class I by roughly 10% (143 , 148), and has no
effect on MHC class I presentation in HEK293 cells (148) under normal conditions. 
addition, ERAP 1 knockdown has no effect on MHC class I presentation in IFNy-treated
cells (143 , 148). Since this data is in agreement with the observations of ERAPI
knockdown in murine cells (141), the authors suggest that the siRNA used by York, et al.
may have caused non-targeted effects that are responsible for the observed phenotype
(148).
Lymphocytes from ERAPI knockout mice also demonstrate a measurable
reduction in MHC class I presentation (149)(York, et al. manuscript in preparation), and
peptides from ER-targeteq precursors are presented poorly in ERAPI-/- fibroblasts also
deficient in TAP (149). ERAPI mice also demonstrate a skewed immunodominance of
epitopes from some viruses (Y ork et al. manuscript in preparation), a reduced immune
response to HY antigens , and an altered peptide repertoire (149), suggesting that ERAP 
plays a major role in MHC class I peptide processing in the ER.
ERAP 1 has also been suggested to act in concert with a newly identified luminal
aminopeptidase ERAP2 (143), which has variable expression in human tissues (150) and
is not present in mice (143), but may playa role in MHC class I peptide generation (150).
These two IFN-inducible proteins were shown to cooperatively trim model HIV antigens
based on sequence preference in microsomal extracts , and in living cells treated with
siRNA (143).
Other peptidases in the secretory pathway have also been associated with antigen
processing. Furin is a trans-Golgi network protease that is involved in the processing of
a number of pro-proteins , and has also been suggested to playa role in the processing of
MHC class I peptides derived from the secreted form of the HBV core protein (151 , 152)
and from the HIV gp160 protein (152).
When signal sequences were found to be presented by HLA-A2 molecules
investigators thought that signal peptidase might playa role in generating these pep tides
for MHC class I presentation (153 , 154), however studies directly addressing this
possibility have not been forthcoming.
Other ER-localized or membrane bound aminopeptidases that have not been
linked to antigen presentation but merit consideration are PLAP/lRAP/oxytocinase (EC
3.4. 11.3), aminopeptidase N (CD13) (EC 3.4. 11.2), glutamyl aminopeptidase (EC
3.4. 11.7), and aminopeptidase P (EC 3.4. 11.9).
Peptide destruction can prevent presentation by MHC class I
Aside from their ability to generate MHC class I peptides , most aminopeptidases
can trim peptides down to the size that they can no longer bind MHC class I molecules.
For example , PSA has been shown to degrade the Sendai virus nucleoprotein epitope
APGNYP AL in cytosolic extracts (59). Purified BH and PSA can both destroy the
VSV nucleoprotein epitope (60). Overexpression studies have shown that LAP can
reduce the MHC class I peptide pool (28 , 68). TPPII is cUlTently thought to trim longer
peptides , but it has been shown to effciently degrade short fluorogenic substrates in vitro
(107), demonstrating that it can degrade short peptides as well. TPPII is also thought to
be responsible for the destruction of some MHC class I peptide precursors in living cells
(54). Together, these data suggest that cytosolic aminopeptidases can destroy MHC class
I peptides.
Other cytosolic peptidases can destroy MHC class I peptides as well. Thimet
oligopeptidase (TOP) (EC 3.4.24. 15) is an endopeptidase that hydrolyzes peptides that
are 6- 17 amino acids in size (155). It was initially reported to have a role in antigen
processing in 1999 when Portaro et al. used recombinant TOP to show that TOP
endopeptidase activity is inhibited by antigenic peptides (156). They further suggested
that TOP acts as a peptide chaperone in the cytosol rather than an endopeptidase that
degrades antigenic peptides (156). Treatment of cells with a TOP inhibitor reduced
activation of epitope-specific CTLs , suggesting that the chaperoning activity of TOP was
required for CTL activation (157).
However, these conclusions are not without conflict. Portaro et al. also showed
that the majority of tested peptides (including SIINFEKL precursors), were stable in the
cytosol for long periods of time (156). Yet Saric , et al. has shown that incubation of
antigenic peptides in cytosolic extracts leads to rapid degradation of the peptides , mainly
by TOP (59). Upon immunodepletion of TOP from He La celllysates , degradation of a
decapeptide library was reduced by roughly 33% (57). In addition, reducing TOP protein
via siRNA leads to increased levels of SIINFEKL presentation (158), and increases
overall MHC class 1 presentation (158 , 159), suggesting a role for TOP in MHC class I
peptide destruction. Overexpression of TOP led to suppression ofMHC class I
presentation (159). It also led to decreased presentation of SIINFEKL and other
antigenic pep tides from minigenes expressed in the cytosol (158), peptide precursors
(68), and full length proteins (158), but not ER-targeted minigenes (158). Together, these
data suggest that TOP limits the size of the MHC peptide pool by degrading peptides in
the cytosol.
Object of this work
The goal of this work has been to define the role(s) ofcytosolic aminopeptidases
in the generation of peptides for antigen presentation. There was evidence to suggest that
a number of aminopeptidases might be involved in this process. The questions that have
been addressed by my work relate specifically to three aminopeptidases: LAP, PSA, and
BH. These aminopeptidases were chosen because they are all localized in the cytosol
and were all identified previously as candidates for having a role in peptide generation.
Theoretically, aminopeptidases might play unique roles. Alternatively, some
aminopeptidases may act in concert as has been suggested by two previous studies (61
143). And finally, the broad specificity that these aminopeptidases exhibit in vitro may
allow them to be functionally redundant in vivo for some or all peptide trimming. The
work that I present here suggests that the latter is true , and that the functions of LAP , BH
and PSA in generating peptides for MHC class I presentation is mostly redundant.
To demonstrate this , a series of experiments were performed involving antigen
presentation assays in cultured cells that arc aminopeptidase-deficient and/or are knock-
down cells (RNAi) with reduced aminopeptidase expression. In addition, MHC class I
antigen presentation was examined in a series of aminopeptidase-deficient mice.
Of course , one of the main functions of the MHC class I presentation pathway is
to help the immune system detect infection, and we hypothesized that LAP , PSA and/or
BH could contribute to the generation of antigenic viral epitopes. To address this
hypothesis, the presentation of specific CTL epitopes was examined under the conditions
of viral infection in mice. The conclusion is that these aminopeptidases are redundant in
generation of viral epitopes (or at least those that have been examined).
CHAPTER II
MATERIALS AND METHODS
Plasmids, primers, and PCR
The plasmids llsed to make the HL3F. l and control cell lines were generated by
designing shRNA inserts using RNAiOligoRetriever software and were based on the
NCBI sequence for human LAP NM 015907. Synthetic oligos (IDT , Coralville , IA)
were inserted into BseRI and BamHI digested pSHAG- l plasmid (160)(a gift of Dr. G.
Hannon, CSH Labs). The oligos are listed in Table 1
Kanamycin-resistant bacterial clones were selected and the plasmids were sequenced.
pSHAG+shRNA plasmids were digested with Pvull and the fragment including the U6
promoter and shRNA sequence were sub cloned into pTracer-CMV2 (Invitrogen
Carlsbad, CA) which had been digested with NruI and EcoRV, removing the CMV
promoter.
Primers used for identification of shRNA knock-down clones and for real-time PCR are
included in Table 2.
The SIINFEKL mini (MSIINFEKL), N5+SIINFEKL (LEQLESIINFEKL),
N25+SIINFEKL (LPF ASGTMSML VLLPDEVSGLEQLESIINFEKL), and full-length
OV A genes were all subcloned from other vectors into pTracer-CMV2 (Invitrogen
Carlsbad, CA), a plasmid containing a GFP/Zeocin-resistance fusion protein by
restriction digest and ligat on. The plasmids were then sequenced to confirm correct
sequences and reading frames. The pcDNA3. N5+SIINFEKL plasmid, which was used
in some experiments , does not contain a GFP gene and has been described previously.
To express mature SIINFEKL with no N-terminal residues , we constructed pUG-
SIINFEKL , and other pUG plasmids as listed in Table 3 . These plasmids consist of
ubiquitin with SIINFEKL (or SIINFEKL precursor) fused to the C terminus; C-terminal
ubiquitin hydrolases effciently release peptides thus fused to ubiquitin (163). An
internal ribosome entry site (IRES) downstream of the ubiquitin-SIINFEKL fusion was
followed by GFP.
mRNA was isolated from 10 cells using anRNeasy kit (Qiagen, Valencia, CA). cDNA
was synthesized using Superscript II enzyme (Invitrogen, Carlsbad, CA) and real-time
PCR was performed on an iCycler machine (BioRad, Hercules , CA) with Sybergreen
buffer (Applied Biosystems , Foster City, CA), or a MyIQ machine (BioRad, Hercules
CA) with BioRad 2X Master mix (BioRad, Hercules , CA).
For screening of ES cells that contained an LAP knock-out allele, TaqmanrI primers
were used and are listed in Table 2 . Each TaqmanrI primer sequence spanned the point
of recombination between the reporter gene and endogenous genomic sequence. Three-
primer PCR protocols were used to screen for LAP-deficient and PSA-deficient mice.
Primers are listed in Table 2 . LAP-WT(Rl) (or mPSA-R2) lies downstream of the knock-
out insert in the genomic sequence, and therefore amplifies both the wild type and knock-
out alleles. LAP-KO(F5) (or mPSA-KO(F1)) lies within the knock-out allele , and
amplifies only the knock-out allele. LAP-WT(Fl) (or mPSA-WT(F3)) lies within the
wild-type allele and amplifies only the wild type allele.
Generation of LAP-
/- 
mice
The mouse LAP gene (GeneID: 66988) was deleted using VelociGene(g technology
(164). Briefly, a large targeting vector (BACvec) was constructed by bacterial
homologous recombination in which the 19.2 kb LAP gene was replaced by a lacZ-neo
cassette. An 129xC57BL/6 Fl ES cell line was electroporated with the BACvec and
selected for G418 resistance. Drug-resistant clones were screened for loss of one copy of
the LAP gene by quantitative PCR using probes at either end of the deletion. Two
independent targeted ES cell clones were microinjected into C57BL/6 blastocysts , which
were implanted in C57BL/6 females to generate chimeras. Chimeras were bred back to
BL/6 to generate Fl heterozygote mice. Both ES cell clones produced healthy appearing
knockout mice in proper Mendelian proportions. A line derived from one of these clones
was used for subsequent experiments.
Generation of PSA-
/- 
mice
The mouse PSA (NPEPPS) gene (GeneID: 19155) was deleted using VelociGeneCI
technology (164), just as tl"e LAP mice. Briefly, a large targeting vector (BACvec) was
constructed by bacterial homologous recombination in which 18. 1 kb of the PSA gene
(Exons 3-9) were replaced by a lacZ-neo cassette. An 129xC57BL/6 Fl ES cell line was
electroporated with the BACvec and selected for G418 resistance. Drug-resistant clones
were screened for loss of one copy of the LAP gene by quantitative PCR using probes at
either end of the deletion. Two independent targeted ES cell clones were microinjected
into C57BL/6 blastocysts , which were implanted in C57BL/6 females to generate
chimeras. Chimeras were bred back to BL/6 to generate F 1 heterozygote mice. A line
derived from one of these clones was used for subsequent experiments
Poly I:C treatment of mice
For LAP studies , mice were injected interperitoneally with 200/-g of poly I:C (Amersham
Pharmacia, Piscataway, NJ) in a total volume of 200I-L PBS (Gibco , Logan, UT).
Spleens from the mice were harvested after 24 hOllrs and then stained for flow cytometric
analysis.
Virus infection of mice
Mice were injected IP with 5x10 pfu/ mouse of LCMV Armstrong (a gift from Dr. Ray
Welsh, University of Massachusetts Medical School, Worcester, MA), or with 5xl06 pfu/
mouse ofrecombinant vaccinia (provided by Drs. Jon Yew dell and Jack Bennink, NIH
Bethesda, MD), containing chicken ovalbumin (21). Mice were infected IV with 5x10
pfu/ mouse of Vesicular Stomatitis Virus (VSV) (a gift from Dr. Ray Welsh), or with 50-
100 HAU of Sendai virus (a gift from Dr. Kate Fitzgerald). Eight or nine days (LCMV),
7 days (Vac-OV A and VSV), or 6 days (Sendai) post-infection, splenocytes were
harvested and incubated for 5 hours with the appropriate peptide (51J for LCMV , Vac-
OVA, and Sendai; 2-51J for VSV), or with anti-CD3E (BD Biosciences , San Jose , CA)
in the presence of GolgiPlug (BD Biosciences , San Jose , CA), and recombinant IL-2 (BD
Biosciences , San Jose , CA). Vaccinia peptides that were used to stimulate IFNy
production were B8R (TSYKFESV) (165), SIINFEKL, and P10 (STLNFNNL) (166).
LCMV pep tides included gp33 (KA VYNFATC), gp276 (SGVENPGGYCL), NP205
(YTVKYPNL), and NP396 (FQPQNGQFI). The VSV peptide (RGYVYQGL), and Sendai
peptide (F APGNYP AL) were also used. All peptides were synthesized (Anaspec , Inc.
San Jose , CA). Cells were then stained for CD8 , CD44 , and intracellular IFNy using
commercial antibodies (BD Biosciences , San Jose , CA), and analyzed by flow cytometry
Construction of stable shRNA cells
HeLa- cells (142) were transfected with the shRNA+GFP/Zeocin resistance-expressing
plasmids using HeLa Monster (Mirus , Madison, WI). 48 hrs after transfection, the cells
were serially diluted in DMEM containing 100 Ilg/mL of Zeocin (Invitrogen, Carlsbad
CA) to select for plasmid transfectants and seeded in 96-well plates. After 14 days of
incubation in selection media, clones were isolated and tested for expression of LAP
mRNA by RT-PCR and GFP expression by FACS. Clones used in these studies were
selected based on comparable expression of GFP.
Cells and tissue culture
shRNA knock-down cell lines were incubated at 37 C and 10% CO in DMEM+ 10%
FCS , 100 ).g/mL Zeocin to select for cells expressing the shRNA, and 100 ).g/mL G-418
(Invitrogen, Carlsbad, CA) to select for cells expressing H- . Mouse Embryonic
Fibroblasts (MEFs) were generated from 12- 14 day embryos and cultured at 37 C and
10% COz in DMEM+20% FCS. Cells were cultured in flasks , and transfections were
performed in 6-well plates (Corning-Costar, Acton, MA). During transfection periods
cells were cultured in DMEM+ 10%FCS.
For incubations in IFNy, MEFs or shRNA knock-down cells were transfected first with
the indicated construct. Then 8 hrs later, the transfection media was removed and
DMEM+FCS+IFNy was added to each well. The IFNy concentrations used were 250
Units/ml recombinant human IFNy for HeLa cells (Biogen, Cambridge, MA), or 50
Units/mL recombinant murine IFNy for MEFs (BD Biosciences , San Jose , CA). The
cells were incubated in IFNy until the cells were analyzed.
Antibodies, immunoblotting, and flow cytometry
The mAb 25.D1.16 (anti- +SIINFEKL) (167), AF6-88. 5 (anti- ) (168), Y3 (anti-
(169), M1I42 (anti-H2) (170), or (anti-influenza HA) (a gift ofW. Gerhard, The
Wistar Institute , UPENN) were used as primary antibodies in staining HeLa cells and
MEFs for flow cytometry. After incubation in one of the primary antibodies, the cells
were washed with PBS and stained with donkey anti-mouse (or donkey anti-rat) F(ab'
fragments conjugated to Cy5 (Jackson Immunoresearch, West Grove , PA). For staining
cells isolated from spleen, AF6-88. 5 (H- ) and KH95 (H- ) antibodies conjugated
to a fluorophore were used according to the manufacturer s directions (BD Biosciences
San Jose , CA). The cells were then analyzed by flow cytometry on a FACSCalibur
apparatus (Becton Dickinson, San Jose, CA) with FlowJo software (Tree Star, San
Carlos , CA).
For immunoblotting HeLa cells , cells were lysed in a ImL Dounce homogenizer on ice in
Dounce buffer 10mM Tris-HCL , 0. 5mM MgCl pH 6. Complete mini EDTA-free
protease inhibitor cocktail tablets (Roche , Nutley, NJ) were added according to
manufacturer s instructions. After 50 strokes in the Dounce homogenizer, stabilization
buffer was added (lOmM Tris-HCL , 0.5mM MgC12 , 0. 6M NaCl , and complete mini
tablets) to the lysate to stabilize the nuclei. After a 5-minute spin in a mini-centrifuge at
C at full speed, the resulting supernatant was centrifuged at 4 C in an ultracentrifuge
(Beckman, Fullerton, CA) with a 70. 1 Ti rotor (Beckman) at 35 000 rpm for Ihr. 3X SDS
sample buffer + DTT (NEB) was added to the resulting supernatant and the samples were
heated to 95 C for 5min.
For immunoblotting MEFs , cells were lysed by adding NP40-lysis buffer (1 % NP40
300mM NaCl , 50mM NaH P04) with complete mini EDTA-free protease inhibitor
cocktail tablets added (Royhe , Nutley, NJ) according to manufacturer s instructions.
After a 5-minute incubation on ice , they were spun in a mini-centrifuge at 4 C at full
speed for 5 minutes. 3X SDS+DTT buffer was added to the resulting supernatant and the
samples were heated to 95 C for 5min.
1.5xl05 HeLa cell equivalents (or 3xl0 for MEFs) were run on a 12% SDS gel followed
by protein transfer to a nitrocellulose membrane (Schleicher & Schuell Bioscience
Keene , NH). After transfer, the membrane was rotated overnight in PBS+5% milk+
2% Tween20 to block. After 18 hrs , the membrane was stained with rabbit anti-LAP
polyclonal antibody (a gift from Dr. Alfred Goldberg, Harvard Medical School) diluted
1:10 000 in PBS+0.2% Tween+0.02% NaN . After 2 hrs , the blot was washed three
times with PBS+0.2%Tween for 30 min. The blot was then stained with horseradish
peroxidase-conjugated goat anti-rabbit diluted 1 :50K. The blot was developed with
enhanced chemiluminescence (Pierce , Rockford, IL). The same protocol was followed
using two different polyclonal anti-BH antibodies that were diluted 1 :25 000 (a gift from
Dr. Paul O' Farrell, Cold Spring Harbor Laboratories) or 1:500 (a gift from Dr. Jacques
Neefjes, The Netherlands Cancer Research Institute), and the HRP-conjugated antibody
diluted 1 :25 000.
CHAPTER III
RESULTS
Leucine aminopeptidase is not essential for trimming
peptides in the cytosol or generating epitopes for MHC class I
antigen presentation
1 Generation of LAP deficient mice
LAP deficient mice were generated by and purchased from Regeneron using
VelociGeneCI technology (164). Homologous recombination resulted in a loss of all
exons and introns of the LAP genomic sequence (Fig lA) , beginning 6 bp downstream of
the LAP start codon, and ending 624 bp after the LAP stop codon. In total
approximately 19. 2 kb was deleted. Presence of the neogene and subsequent loss of the
entire LAP gene was confirmed by PCR (Fig IB). LAP -/- mice express no LAP protein
in any of the organs tested (Fig lC), even after IFN stimulation (Fig ID
2 Lymphocyte ratios and MHC class I levels in LAP -/- mice are
normal
Since MHC class I surface expression is dependent on peptide supply, changes in
peptide supply can be detected by measuring surface MHC class I levels. Elimination 
LAP could in principle reduce peptide supply to MHC class I (if LAP predominately
trims peptides longer than 9- 10 amino acids) or increase peptide supply (if LAP
preferentially trims peptides 9 to 1 0 amino acids in length that could otherwise bind to
MHC class I). We therefore evaluated the expression ofMHC class I on cells in the LAP
deficient animals. The levels of H - and H - as well as the overall amount of total
MHC class I on splenocytes from LAP-/- mice were similar to those on splenocytes from
wild- type C57BL/6 mice (Fig 2) . The small reduction in K expression on LAP-/- cells
in this experiment was not statistically significant and was not observed in other
experiments. LAP is normally induced by IFN (53 , 78), and in wild-type mice LAP
protein levels increased after intraperitoneal injection of the type I IFN-inducer poly I:C.
However, even under these conditions surface levels of H- and H- were not
significantly different in wild type and LAP -/- mice (Fig 2
Mice lacking important components of the MHC class I antigen presentation
pathway sometimes have reduced levels of CD8+ T lymphocytes due to reduced positive
selection in the thymus (44 , 171 , 172). Therefore , we examined the levels of CD8 T cells
in the LAP-deficient mice. Inguinal, mesenteric , and cervical lymph nodes and spleens
were harvested from C57BL/6 and LAP -/- mice and their CD4 and CD8 T cells were
enumerated by flow cytometry. CD4+ B220- cells , and CD8+ B220- cells were present
in similar ratios and numbers in both strains , suggesting that T cell generation and
maturation is grossly normal in LAP -/- mice (Fig 3
3 LAP -/- MEFs present peptide as well as wild type MEFs
Several independent lines of mouse embryonic fibroblasts (MEFs) were generated
from WT and LAP-/- embryos. As with lymphocytes , no significant differences in
surface H- , H- or total MHC class I levels were detected either under normal
conditions or after stimulation with IFNy (Fig 4) . Using real time PCR, we detected a
large amount of variation in the expression ofBH, PSA, and ERAPI mRNAs among all
MEFs (Fig 5 ), however there was certainly no pattern of increased expression of these
aminopeptidases in the LAP-/- MEFs. Therefore , these other aminopeptidases were not
upregulated and compensating for a lack of LAP.
Cleavage of full-length ovalbumin by the proteasome in vitro generates
SIINFEKL , as well as SIINFEKL extended at the N-terminus by up to 12 residues (50).
Similarly, N-extended precursors of SIINFEKL are generated from full- length ovalbumin
constructs and require trimming for presentation in vivo (142). To examine the role of
LAP in this process , we transfected wild type or LAP -/- MEFs with plasmids expressing
full-length ovalbumin and GFP, so that transfected cells could be identified by GFP
expression. Wild type and LAP -/- MEFs (gated for comparable GFP expression)
generated similar amounts of SIINFEKL- complexes (Fig 6A) as detected by flow
cytometry using the H- SIINFEKL-specific antibody 25.D1.16 (167).
To more thoroughly examine the dependence of the processing ofN-extended
peptides on aminopeptidases , we expressed in these MEFs N-extended forms of
SIINFEKL from minigenes. In this situation, all of the peptides are produced in the
cytosol as precursors that require trimming for presentation (39 51). SIINFEKL
generation from precursors extended by 1 (the initiating methionine) or 5 residues , was
identical in wild-type and LAP-/- MEFs (Fig 6A). Since these 9- 13 residue antigenic
precursors can be transported into the ER and trimmed by ERAPl (142), we also
examined the presentation of a 33 residue precursor that is too long to be effciently
transported into the ER by TAP (125). This construct, which has a 25 residue N-terminal
extension, was trimmed and presented similarly by wild type and LAP-/- MEFs (Fig 6A
Therefore , under constitutive conditions, LAP is not essential for the trimming ofN-
extended SIINFEKL precursors.
Aminopeptidases can also destroy antigenic peptides by trimming them below the
size required for stable binding to MHC class I molecules. To test whether LAP might be
destroying some presentable peptides , MEFs were transfected with a construct encoding a
ubiquitin-SIINFEKL fusion protein. When expressed in cells, the N-terminal ubiquitin is
cleaved, thereby producing the mature epitope SIINFEKL. If LAP were to trim
SIINFEKL the resulting products would not bind stably to H- . However, LAP- ; and
wild type cells presented equivalently SIINFEKL generated from the ubiquitin fusion
construct (Fig. 6A). Therefore , LAP is not limiting the amount of SIINFEKL available
for presentation.
Interferon treatment of cells alters the composition and enzymatic activities of the
proteasome , resulting in relatively more N-extended precursors of antigenic epitopes
(50), as well as increased levels of LAP (53). However, even though IFN treatment
increased overall presentation, the presentation of SIINFEKL from each precursor was
the same in wild-type and LAP -/- MEFs (Fig 6B) suggesting that even at induced levels
LAP is not essential in the generation of some MHC class I peptides.
4 Presentation of viral epitopes is not altered in LAP -/- mice
To test antigen processing in vivo we examined the CTL response to several
viruses. Wild type and LAP -/- mice were infected with vesicular stomatitis virus (VSV),
LCMV , or a recombinant vaccinia virus expressing ovalbumin. At the peak of each
infection, splenic lymphocytes were isolated, stimulated in vitro with the appropriate
antigenic peptide , and stained for intracellular IFNy levels. The frequency of responding
(IFNy-positive) CTL (Fig. 7) and their level of production ofIFNy (data not shown) to
the VSV peptide (Fig 7 A), to four antigenic LCMV peptides (Fig 7B), and to two
recombinant Vac-OV A pep tides (Fig. 7C) in LAP -/- mice was equal to that of wild-type
mice , suggesting that neither the quantity nor the quality of the CTL response in vivo was
dependent on LAP.
5 LAP mRNA expression and protein levels are reduced in shRNA
stable transfectants of HeLa cells
The findings that elimination of LAP does not alter antigen presentation in mouse
cells , both in vivo and in vitro was unexpected, since LAP has been shown to process N-
extended SIINFEKL peptides in celllysates (53). Because the previous studies used
HeLa cell extracts , it seemed possible that LAP might playa more important role in
human cells or in particular cell types. To investigate this issue , HeLa- cells (142)
were stably transfected with a plasmid encoding a short-hairpin RNA (shRNA) targeting
LAP , or encoding a control shRNA that does not recognize human sequences. Clone
LAP-KD showed a reduction in LAP of90-95% by real time PCR (Fig 8A) and western
blot (Fig 8B), as compared to the control cell line. Real-time PCR analysis showed a
slight increase in BH and PSA mRNA in LAP-KD cells , however this may be due to
clonal variation between cell lines or to a difference in ~-actin mRNA levels between
these cells since ~-actin mRNA was used for normalization (Fig 9)
LAP is inducible by IFNy in HeLa cells (53). Therefore, we examined the
silencing of LAP in LAP-KD cells treated with IFNy. After 48 hr of IFNy treatment
LAP mRNA was increased approximately 10-fold in the control cell line (Fig 8A), but
LAP mRA levels in the LAP-KD cell line, while increased, were still approximately
95-99% lower than in the control (IFN-stimulated) cell line. Analysis of protein levels by
semi-quantitative immunoblotting gave similar results (Fig. 8B). LAP-KD constitutively
had approximately 5- 10% as much LAP as the control cell line. While treatment with
IFNy increased the levels of LAP protein approximately lO-fold in both the LAP-KD and
control cell lines , LAP levels in LAP-KD were about lO-fold lower than in control cells
treated with IFNy.
6 Stable shRNA does not induce IFN-sensitive genes
Expression of shRNA from plasmids has been suggested to induce transcription
ofIFN-sensitive genes (173 , 174). Because MHC class I levels are also affected by IFN
such induction could skew any phenotype observed in the LAP-KD cell line. To
determine if either of these shRNAs constitutively induces IFN-sensitive genes in LAP-
KD cells , real-time PCR assays were used to measure mRA levels of protein kinase R
(PKR), and interferon-sensitive gene 15 (ISG 15), which are activated by IFN (175).
In LAP-KD and shRNA control cells , expression ofIFN-sensitive genes were the
same even after incubation with poly I:C , suggesting that low level expression of these
shRNAs does not induce transcription ofIFN-sensitive genes (Fig 10
7 Reduction of LAP has no effect on surface presentation of H-
+ SIINFEKL in HeLa cells.
Since LAP was originally described as an enzyme in He La cell extracts that
trimmed N-terminally extended precursors of the OVA peptide SIINFEKL, we tested
such peptides in the LAP-KD cells. Therefore , LAP-KD cells and control cells were
transiently transfected with plasmids encoding ovalbumin or N-extended SIINFEKL
precursors, as described above. For each of the constructs , the generation ofH-
SIINFEKL was the same in control and LAP-KD cells (Fig. lIA). There was also no
difference between the control and LAP-KD cells when they were treated with IFNy (Fig
IIB). Therefore , LAP is not required for generation ofMHC class I peptides in HeLa
cells.
terminally extended peptides may be transported to the ER by TAP, where they
can be trimmed to mature epitopes by ERAPl. To determine ifERAPI was masking an
effect of LAP deficiency, we examined the phenotype of cells in which both LAP and
ERAPl were silenced. LAP-KD and control cells were treated with an siRNA targeting
ERAP1 , or with control siRNA (142) and then transiently transfected with plasmids
encoding N-terminally extended SIINFEKL precursors , as described above. As
previously reported (142), presentation of SIINFEKL from N-extended precursors is
reduced in HeLa cells treated with ERAPI siRNA (Fig 12). In comparison , SIINFEKL
presentation was not further reduced in LAP and ERAP 1 double-KD cells. Presentation
of the SIINFEKL precursor was also not different in ERAP I-deficient versus LAP +
ERAP i-deficient cells after stimulation with IFNy for 24 hours post- transfection (Fig 12
8 Reduction of LAP has no effect on the rate of peptide trimming
in cells.
The quantitation of antigen presentation is an indirect measure of the generation
of antigenic peptides. It is possible that a contribution of LAP to this process could be
missed if the trimming of pep tides was not a rate-limiting step in the pathway. Therefore
we sent the LAP-KD cells and control cells to Joost Neijssen and Jacques Neefjes so that
they could directly measure the rate of peptide degradation in these cells by
microinjection of pep tides containing fluorescein and quencher adducts (28 54). These
substrates generate a fluorescent signal when aminopeptidases cleave and thereby
separate the residues containing the fluorophore and quencher moieties. Peptides with
different amino acids in the PI position were microinjected into cells , and the
fluorescence resulting from trimming the peptides was measured.
Although there was some variation in the rate of trimming of different peptide
sequences , there was no statistically significant difference in the half-life of any of the
tested peptides between the two cell lines (Fig. 13A). Treating the cells with IFNy prior
to microinjection increased LAP expression (Fig. 13B), but did not alter the rate of
processing of the peptides (Fig. 13A & C). These data demonstrate that LAP activity
does not influence the rate of peptide trimming in the cytosol.
Bleomycin Hydrolase is not essential for trimming peptides
in the cytosol or generating epitopes for MHC class I antigen
presentation
1 siRNA reduction of BH may not affect MHC class I presentation
siRNA is a powerful tool that has been used by a number of groups to examine
the effect of transient loss ofaminopeptidases in living cells (54 , 141 , 142 , 158)(York, et
al. submitted). To examine the role ofBH in human cells , two siRNA sequences were
designed to target BH mRNA. Both siRNAs reduced BH mRNA levels in HeLa- cells
compared to mTOP control siRNA (which targets murine TOP) (Fig 14). However, they
had different effects on endogenous MHC class I presentation in HeLa- Fig 15)
Transfection ofBH siRNA#1 had little effect on levels ofMHC class I presentation
whereas transfection of BH siRNA#2 caused an overall increase in MHC class 
Because BH is a processive enzyme, a small amount of enzyme could account for
the observed difference , and it is possible that some residual protein not knocked-down
by BH siRNA#l could account for the discrepancy between phenotypes. An alternative
explanation is that one of the BH siRNA sequences increases transcription of type-I IFN.
Since many components of the MHC class I pathway are sensitive to IFN expression, this
could be influencing the MHC class I presentation pathway independently of BH activity.
siRNAs , originally designed as 21 mers , were thought to be too short to bind Toll-
like receptor 3 (TLR3) or activate enzymes like Protein Kinase R (PKR) and
Oligoadenylate Synthase (OAS) (176 , 177). They were also thought to target only
mRNAs with 100% homology for degradation. However, others have shown that
siRNAs can activate IFN-sensitive genes (173 178 179) and bind TLR3 (173 180 181).
In addition, siRNAs have also been shown to alter gene expression of mRNAs with less
than 100% sequence homology to the siRNA (off-target effects) (182 , 183). To address
whether either of these postulated siRNA "side-effects" could explain the contrast in
phenotypes of cells transfected with BH#1 or BH#2 siRNA, a series of experiments were
designed and performed.
HeLa cells were transfected with BH#l , BH#2 , mTOP , or Luc1 which is a siRNA
sequence that has been shown to increase transcription of IFN-sensitive genes , but does
not have a target mRNA in human cells (173). After siRNA transfection, mRNA was
isolated at varying time points to measure transcriptional induction of OAS2 , PKR, and
interferon-sensitive gene 15 (ISG 15). Transcription of all of these genes is stimulated by
IFN, and they are often used to measure IFN-signaling (175).
Results from real-time PCR suggest that siRNAs can affect these genes at
different levels (Fig 16). As expected, Luc1 siRNA increased expression ofISG 15 , PKR
and OAS as compared to mTOP control siRNA (Fig 16A) . Transfection ofBH#l did not
induce any of the genes tested and had lower amounts of all transcripts, even compared to
the mTOP control (Fig 16B) . In contrast, BH#2 siRNA induced expression of ISG 15 to
levels higher than Luc 1 , but did not significantly enhance transcription of PKR or OAS2
Fig 16) . Together these data suggest that BH#2 siRNA has physiological effects other
than the reduction ofBH mRNA, and that like Luc1 , BH#2 may upregulate IFN-sensitive
genes such as proteins involved in MHC class I machinery, and thereby enhance surface
presentation. In support of this conclusion , HeLa cells transfected with Luc 1 or BH#2
siRNA show comparable increases in MHC class I presentation (Fig 17), and COS-
cells transfected with these siRNAs show similar decreases in SIINFEKL presentation
when expressing SIINFEKL peptide precursors (Fig 18)
Although it is possible that an increase in MHC class I presentation may be due to
an intracellular IFN response , it is stil formally possible that transfection of BH#2
siRNA demonstrates the accurate phenotype , whereas BH# 1 transfection ineffciently
reduces BH protein. To address the question of whether the observed phenotype was
specifically due to the ability of BH#2 to knock down BH mRNA, other siRNAs were
designed to target the 3' untrans1ated region (UTR) of the BH mRA , which is located
after the stop codon in the mRNA transcript. Such an siRNA wil target endogenous BH
mRNA that has been properly processed from pre-mRNA, but will not be able to target
an open reading frame (ORF) that lacks a 3 ' UTR. By real time PCR, this new siRNA
(BH-UTR) was shown to knock down BH mRNA as well as BH#2 (Fig 19) . In addition
it was just as effective (or more effective) than BH#2 and Luc 1 in reducing SIINFEKL
presentation from peptide precursors in HeLa- Fig 20A) and COS- cells (Fig20B
2IB
COS- cells were transfected, with Lucl , mTOP , or BH-UTR siRNA. Then 24
hours later (day 1), the cells were transfected with a plasmid expressing a SIINFEKL
precursor, and BH-ORF or vector control. On day 3 , the cells were counted, and
analyzed by flow cytometry for presentation of SIINFEKL , and by real-time PCR for
expression ofBH mRNA. If the reduction ofSIINFEKL presentation was due to the
knockdown ofBH mRNA by BH#2 , then overexpression ofBH-ORF (which is not
targeted by BH-UTR) would ameliorate the phenotype. Overexpression ofBH-ORF
resulted in high levels ofBH mRNA (indicating that the BH-ORF , was not reduced by
BH-UTR) (Fig 21A). However, this increase did not ameliorate the decrease in
SIINFEKL presentation (Fig 21 C), suggesting that the reduction of SIINFEKL
presentation by BH#2 , BH-UTR, and Lucl is likely the result of an effect other than their
effciency at knocking down BH.
These studies demonstrate that although RNAi (siRNA) is a powerful
experimental tool, care should be taken in the interpretation of data since off-target
effects may account for phenotypes that may initially be attributed to the reduction of the
target. To ensure that observed phenotypes are due to silencing of the target gene , proper
experimental controls (such as multiple siRNAs) are essential. In the case ofBH, it is
clear that knockdown by siRNA demonstrated phenotypes that were inconclusive, and
emphasized the desirability for an alternative system of study.
2 BH -/- MEFs present peptide as well as wild type MEFs
To examine antigen presentation in cells deficient in BH, BH-deficient and wild
type control MEFs were generated (Fig 22A). Levels of MHC class I were measured by
flow cytometry to detelmine if there were any defects in antigen presentation. Overall
expression ofH- (Y3 and B8) and all MHC class I (M142) were comparable between
BH-deficient and wild type MEFs (Fig 22B
To compare the ability of BH-/- MEFs to present one specific model peptide
(SIINFEKL), MEFs were transfected with a series of constructs encoding GFP and
ubiquitin-fusion minigenes. In these plasmids , the C-terminus of ubiquitin is fused to an
N-extended form of the SIINFEKL peptide. These minigenes mimic an in vivo ligation
of ubi quit in via its C-terminus which can be cleaved by ubiquitin C-terminal hydrolases
163). Such a cleavage results in the peptide of interest with no starting methionine
thus generating peptides more similar to the peptides generated by the proteasome. Using
this system, it is possible to generate a peptide with virtually any N-terminal residue by
varying the amino acid at the ubiquitin-linker junction. Cleavage of ubiquitin from the
peptide, and subsequent trimming of the N-terminal residues can be detected by 25.D1.16
staining oftransfected cells. Two series ofN-terminal extensions were generated in order
to address the possibility that BH is important for trimming some sequences, but not
others. First, the natural upstream sequence of SIINFEKL was used since it has been
used in previous experiments and is known to be trimmed in live cells (39). Second, the
upstream sequence of the VSV nucleoprotein epitope was used since this sequence has
previously been shown to be trimmed by BH and PSA (60) (Table 3
MEFs were transfected with the constructs listed in Table 3 and analyzed by flow
cytometry after 48 hrs. Cells were gated based on comparable GFP expression, and then
compared for SIINFEKL presentation. Although SIINFEKL preceded by the natural
upstream sequence was better presented than SIINFEKL preceded by the VSV NP
sequence , no statistical difference was detected between BH-/- and wild type MEFs
although there was consistently a slight decrease in presentation by the BH-/- MEFs (Fig
23) . This suggests that BH does not play an essential role in generating MHC class I
peptides in vivo either from peptide precursors or full length protein. In addition, the fact
that there was no difference (or only a minor decrease) in presentation of the 0+S8L
construct suggests that BH does not destroy MHC class I peptides either, since any
degradation of this peptide would result in reduced presentation (Fig 23
3 Lymphocyte ratios and MHC class I levels in BH -/- mice are
normal
To examine more carefully the role of BH in vivo MHC class I levels were
measured on splenocytes from wild type and BH-deficient mice. CTLs (CD8+, B220-),
helpers (CD4+ , B220-), B-cells (B220+ , CD4- , and CD8-), and dendritic cells
(CDl1c+, CD86+, CD8+ or CD8-) from BH-/- mice presented MHC class I as effciently
as wild type mice. T -cells and B-cells in the peripheral lymph nodes were also normal in
number and MHC class I expression (data not shown), suggesting that BH is not required
for MHC class I presentation in these cell compartments , or for maturation of T -cells (Fig
4 Presentation of viral epitopes is not altered in BH -/- mice
BH has previously been shown to act on viral epitope precursors to generate the
correct peptide in vitro (60), so it possible that BH may have a role in generating MHC
class I peptides from viral proteins during an infection in vivo. If BH is essential for
trimming viral epitopes for presentation, then BH-/- mice would theoretically mount a
reduced CTL response to these epitopes. To investigate , BH mice were infected with
VSV, LCMV, or rVV+OV A, and the CTL response to known viral epitopes was
analyzed at the peak of each infection via intracellular cytokine staining for IFNy. BH-
deficient mice responded to all eight viral epitopes tested as effciently as wild type (Fig
), indicating that BH is not required for presentation of these viral pep tides in vivo.
5 lack of BH has no effect on the rate of peptide trimming in cells
MHC class I surface expression is an indirect measure of the generation of
antigenic peptides. It is possible that a contribution of BH to this process could be
missed if the trimming of pep tides is not a rate-limiting step in the pathway. We sent the
BH-/- MEFs (and wild type controls) to Joost Neijssen and Jacques Neefjes so that they
could measure the rate of peptide degradation in these cells by microinjection of pep tides
containing fluorescein and quencher adducts (28, 54). These substrates generate a
fluorescent signal when aminopeptidases cleave and separate the residues containing the
fluorophore and quencher moieties. Peptides with different amino acids in the Pi
position were microinjected into cells , and the fluorescence resulting from trimming the
peptides was measured.
Although there was some variation in the rate of trimming of different peptide
sequences particularly with proline and glycine (Fig 26) , there was no statistically
significant difference in the half-life of any of the tested peptides between the two cell
lines (Fig 26B). These data demonstrate that BH activity does not influence the rate of
peptide trimming in the cytosol.
Puromycin-sensitive aminopeptidase is not essential for
trimming peptides in the cytosol or generating epitopes for MHC
class I antigen presentation
1 siRNA reduction of PSA may not affect MHC class I
presentation
To examine the role of PSA in human cells , two siRNA sequences were designed
to target human PSA mRNA (PSA#1 and PSA#2). Transfection of HeLa- cells
resulted in the effcient and equal reduction of PSA mRNA by both siRNAs , as detected
by real-time PCR (Fig 27 A). By transfecting PSA siRNA into COS- cells, and then
overexpressing human PSA in the same cells , a reduction of protein could be observed by
western blot (Fig 27B), suggesting that PSA siRNA could specifically target PSA
mRNA, resulting in the reduction of protein. COS- cells were used for this experiment
due to their highly transfectability and the inability of the anti-PSA antibody to detect
endogenous levels of PSA
Next, MHC class I levels were examined on HeLa- cells transfected with
PSA#l or PSA#2. Overall levels ofMHC class I levels did not change significantly in
cells transfected with PSA#I , but were increased in cells transfected with PSA#2 (Fig
). In addition, COS- cells transfected with PSA#1 siRNA presented SIINFEKL
from peptide precursors as well as cells treated with control siRNA, whereas cells treated
with PSA#2 siRNA presented lower amounts of SIINFEKL (Fig 29). If PSA#2 was
presenting an accurate phenotype, then this would suggest that PSA plays a generally
destructive role in MHC class I presentation with the exception of some peptides , such as
SIINFEKL.
2 Some siRNAs may cause off-target effects unrelated to type I
IFN
In order to determine if one of the PSA siRNAs was causing an increase in type-
IFN , like BH#2 , stimulation ofIFN-sensitive genes was measured by real-time PCR.
Real-time PCR on mRNA harvested from cells transfected with PSA#I , PSA#2 , mTOP
or Lucl siRNA indicated that neither PSA siRNA was eliciting a type I IFN-mediated
response (Fig 30). However, the reason why gene silencing with PSA#l and PSA#2
manifested different phenotypes was still unknown.
A potential explanation as to the reason for the discrepancy came inadvertently in
an experiment examining the role ofBH. COS- cells transfected with a variety of
siRNAs were later transfected with a CMV plasmid expressing human BH. After two
days , the cells were analyzed by western blot and real-time PCR for levels of BH mRNA
and protein. PSA#2 and mTOP siRNAs were both used in this experiment as controls
since neither of them share sequence homology with BH. Surprisingly, PSA#2 siRNA
knocked-down BH mRNA as effectively as BH#1 siRNA (Fig 31A), and reduced
translation of BH mRNA as well as BH#2 siRNA (Fig 31B). Importantly, this ability to
limit overexpression ofBH was not shared by PSA#1 siRNA (Fig 31C). Therefore
barring the possibility that PSA protein plays a role in transcription and/or translation
(which has not been reported), these data suggest that PSA#2 siRNA can affect the
expression of genes unrelated to PSA. This brings into question the relatedness and
relevance of the observed phenotypes.
The previous experiment demonstrates that PSA#2 has effects in the cell other
than the silencing ofPSA, however it does not show that these unrelated effects are the
cause of the increase in MHC class I presentation, or of the decrease in SIINFEKL
presentation. One or both of these phenotypes may be directly linked to the reduction of
PSA protein, and unaffected by the side-effects of PSA#2. To address this question, new
siRNAs were designed that targeted the 3' UTR of human PSA (PSA-UTR). Upon
transfection of HeLa- cells , PSA-UTR siRNA was as effective as PSA#2 at reducing
PSA mRNA (Fig 32A). It also did not appear to activate type-I IFN genes by real-time
PCR (Fig 32B), and demonstrated a reduction of K +SIINFEKL presentation in HeLa-
cells (Fig33A) and in COS- cells (Fig 33B) comparable , but not identical to PSA#2
and control siRNA (Fig 33B
To determine if the gene-specific silencing of PSA could explain the phenotype
elicited by PSA#2 and PSA-UTR, COS- cells were transfected with PSA-UTR siRNA
or control siRNA. The next day (day 1), these cells were transfected with a SIINFEKL
peptide precursor construct, and a plasmid expressing the ORF region of human PSA or
vector. On day 3 , the cells were analyzed for PSA mRNA expression by real-time PCR
and ability to present SIINFEKL by flow cytometry. If PSA protein is required to
ameliorate SIINFEKL presentation in cells treated with PSA-UTR, then cells transfected
with PSA-ORF plasmid should present SIINFEKL as well as mTOP control siRNA since
mRNA from the PSA-ORF is not a target ofPSA-UTR siRNA.
Compensatory overexpression of PSA from PSA-ORF was confirmed by real-
time PCR (Fig 34A), but it did not ameliorate the reduction in K +SIINFEKL
presentation caused by transfection with PSA-UTR siRNA (Fig 34B), suggesting that the
reduction in K +SIINFEKL presentation in COS- cells , and the increased MHC class I
presentation in HeLa- cells are due to unrelated effects ofPSA#2 , rather than the
specific gene-silencing capabilities of this siRNA.
The fact that PSA#1 siRNA was as effective at silencing PSA gene expression as
the others , but did not demonstrate a phenotype, suggests that PSA does not play an
essential role in MHC class I presentation (at least in HeLa- and COS- cells).
However, because the reliability of the assay was brought into question, this conclusion
can not be validated using only siRNA.
3 Generation of PSA-deficient mice
PSA-deficient mice were generated using VelociGeneQ! technology (164)
resulting in a loss of exon 4 through exon 9 of the PSA genomic sequence (Fig 35A). In
total, approximately 18. 1 kb was deleted. Presence of the neogene and loss of the PSA
exons 4-9 was confirmed by PCR (Fig 35B). This deletion includes exon 9 , which
encodes half of the active site.
In contrast to previous reports (184 , 185), we find that PSA-deficient 11ice can
reproduce but are subfertile. At weading, PSA-deficient mice are smaller than wild- type
and heterozygote littermates (Fig 35C) , suggesting that PSA is required for normal
growth. As adult breeders, PSA-/- mice delivered an average litter size from of3.
pups , whereas heterozygous breeding pairs delivered an average of 6.28 pups per litter
suggesting that PSA-/- mice are subfertile (Table 4). Of the mice born to PSA+/-
breeding pairs , only 14. 1 % were PSA-/- which is less than normal Mendelian ratios , and
indicates that PSA-/- mice are subviable as embryos (Table 4
4 Dendritic cells express more MHC class I in PSA-deficient mice
Elimination of PSA could in principle reduce peptide supply to MHC class I (if
PSA predominately trims peptides longer than 8- 10 amino acids) or increase peptide
supply (ifPSA preferentially degrades peptides 8 tolO amino acids in length that can bind
to MHC class I). We therefore evaluated the expression ofMHC class I on lymphocytes
in the PSA-deficient animals. There were no significant differences in surface levels of
MHC class I on CTLs (CD8+ , B220-), T-helper cells (CD4+, B220-), or B-cells (B220+
CD4- and CD8-) isolated from spleen and lymph nodes ofPSA-/- and control mice (Fig
and data not shown). However, splenic CDl1c+ dendritic cells from PSA-/- mice
express more MHC class I than wild type cells. The magnitude of this effect was small
( 11-25% increase) but was reproducible and statistically significant (p.:0.05). In contrast
the expression of MHC class II molecules was equivalent on dendritic cells from control
and PSA-deficient mice. These results suggest that in dendritic cells , PSA normally
destroys a small fraction of peptides that could otherwise be presented on MHC class 
5 The CD8+ T-cell response to viral epitopes is not altered in
PSA-I- mice
To more specifically examine effects of PSA knockout on MHC class I antigen
presentation, we analyzed the response of PSA -/- mice to various viral infections. PSA
mice were infected with LCMV (Fig 37 A), VSV (Fig 37B), rVV+OV A (Fig 37C) , or
Sendai (Fig 37D), and the frequencies of CTL specific for viral peptides was analyzed by
intracellular cytokine staining.
PSA-deficient mice mounted comparable CTL responses to all the viral epitopes
tested a total of 9 peptides , including the VSV nucleoprotein epitope and the Sendai
nucleoprotein epitope , which have both been reported to be substrates for purified PSA
(59 , 60), suggesting that PSA is not required for presentation of these viral peptides 
vivo. Therefore , although PSA may destroy some potential MHC class I peptides in
DC' , this does not affect the ability ofPSA-/- mice to mount a normal CTL response to
many viral epitopes epitopes.
6 PSA I- MEFs present peptide as well as wild type MEFs
To analyze antigen presentation in more detail, we generated PSA-deficient or
control mouse embryonic fibroblast (MEF) cell lines as previously described. These cells
do not express truncated forms of PSA mRNA, as determined by real-time PCR for
transcripts encoding exons 10 and 11 (downstream of the neogene insertion) suggesting
that they do not express truncated fo s of PSA mRNA that could be translated in to
functional protein (Fig 38A). Surface levels of H- , H- , and total MHC class I
were consistently higher in PSA-deficient MEFs , but this difference rarely reached
statistical significance (Fig 38B) , indicating that PSA may not be essential for the
generation ofMHC class I-presented peptides in these cells. LAP and ERAPI
expression was somewhat variable in these MEFs as determined by real-time PCR, but
increases were not limited to the PSA MEFs , indicating that these enzymes are not
upregulated to compensate for the loss ofPSA (Fig 39)
However, MEFs express very low levels of cell-surface MHC class and peptide
may not be limiting for cell surface expression ofMHC class I in these cells. To more
closely examine the processing of specific peptide precursors in PSA-/- cells , MEFs were
transfected with a series of constructs encoding N-extended SIINFEKL precursors fused
to the C terminus of ubiquitin, so that ubiquitin C-terminal hydrolases cleave the
SIINFEKL precursor from ubiquitin (9 , 163). Two series ofN-terminal extensions were
generated in order to address the possibility that PSA is important for trimming some
sequences , but not others. First, the natural upstream sequence of SIINFEKL was used
since it is well characterized and is known to be trimmed in live cells (39) (Table 3
Second, the sequence upstream of the VSV nucleoprotein epitope was used, since this
sequence has previously been shown to be trimmed by PSA in celllysates (60) (Table 3
Full length OVA was used because it is a substrate for the proteasome and would
generate an array ofN-extended peptides that might be dependent on PSA for trimming
Table 3
MEFs were transfected with the constructs listed in Table 3 and analyzed by flow
cytometry after 48 hrs (Fig 40). Cells expressing similar levels of GFP were compared
for SIINFEKL presentation. No statistically significant difference between PSA-/- or
wild-type MEFs was detected in the presentation of SIINFEKL, whether the peptide was
preceded by the natural upstream sequence or by the VSV -NP sequence (Fig 40) . This
suggests that PSA is not required for trimming the VSV -NP upstream sequence , and does
not play an essential role in generating MHC class I peptides in vivo either from peptide
precursors or full length protein. In addition, the fact that there was no difference in
presentation of the SIINFEKL mini gene construct suggests that PSA does not destroy
MHC class I peptides either, since any degradation of this peptide would result in
reduced SIINFEKL presentation (Fig 40
7 lack of PSA has no effect on the rate of peptide trimming in
cells
MHC class I surface expression is an indirect measure of the generation of
antigenic peptides. It is possible that a contribution of PSA to this process could be
missed if the trimming of pep tides is not a rate-limiting step in the pathway. We sent the
PSA-/- MEFs (and wild type controls) to Joost Neijssen and Jacques Neefjes so that they
could measure the rate of peptide degradation in these cells by microinjection of peptides
containing fluorescein and quencher adducts (28 , 54). These substrates generate a
fluorescent signal when aminopeptidases cleave and thereby separate the residues
containing the fluorophore and quencher moieties. Peptides with different amino acids in
the PI position were microinjected into cells , and the fluorescence resulting from
trimming the peptides was measured.
Although there was some variation in the rate of trimming of different peptide
sequences (particularly with Pro , Gly, and Asp) (Fig 41 ), there was no statistically
significant difference in the half-life of any of the tested peptides between the two cell
lines (Fig 41B). These data demonstrate that PSA activity does not influence the rate of
peptide trimming in the cytosol.
CHAPTER IV
DISCUSSION
There is considerable evidence that aminopeptidases are important in trimming
antigenic precursors for presentation. Proteasomes have been shown in vitro (50 , 186)
and in living cells (142) to generate many N-extended precursors. Other experiments
have shown that ifN-extended peptide precursors are expressed or injected into cells
they are trimmed and presented by MHC class I on the cell surface (28 , 39). Processing
of such peptides can occur in the presence of pro tea some inhibitors (35 , 39 187),
indicating that other peptidases in the cell can cleave N-terminal residues.
Aminopeptidases can trim N-extended precursors that have a free amino terminus , but
not if the N-terminus is blocked (28 , 51). And eliminating or inhibiting aminopeptidases
in cells reduces antigen presentation (54 , 60 , 61 , 142). Together, these data suggest that
N -extended precursors are generated during protein degradation and then trimmed by
aminopeptidases.
N-extended peptides that are preceded by an ER- localizing signal sequence are
effciently trimmed to mature epitopes in TAP-deficient cells , demonstrating that
aminopeptidases localized in the ER can generate peptides for presentation (39 , 144
188). In cells lacking ERAPl , N-extended peptides targeted to the ER are not presented
as well (141- 143) indicating that ERAPI plays an important role in trimming in the ER.
However, several lines of evidence indicate that N-extended peptides can also be
trimmed in the cytosol prior to their transport into the ER. First, cytosolic N-extended
SIINFEKL precursors expressed in ERAP I-deficient cells are trimmed and presented
(albeit in reduced amounts), whereas when the same constructs are targeted to the ER
SIINFEKL is not presented (142). Second, peptides preceded by N-extensions of up to
25 amino acids are too long to be effciently transported by TAP , but when expressed in
the cytosol , are stil trimmed and presented by MHC class I in the absence of proteasome
activity (39). Third, cytosolic extracts devoid of ER contaminants can trim N-extended
peptides (53 , 60). Fourth, treatment of cells with inhibitors of cytosolic aminopeptidases
reduces the presentation of some peptides (54, 60). A major unresolved issue in the field
is the identity and extent of contribution of the cytosolic aminopeptidases that participate
in the generation ofMHC class I-presented peptides.
TPPII is a cytosolic peptidase that has been shown to play an important role in
trimming peptides that are longer than about 16 residues (54). However, it remains
unclear which cytosolic aminopeptidase(s) trims shorter pep tides of 15 amino acids or
less. It has also been unclear how much redundancy exists among the cytosolic
aminopeptidases.
LAP is not necessary for mouse viability or generation 
MHC class I peptides
In this study, I show (i) that LAP is not essential for viability or normal
development of mice , and (ii) that LAP does not play an indispensable role in generating
peptides presented by MHC class I under constitutive conditions or after stimulation with
IFN.
LAP is a cytosolic-aminopeptidase that was thought to be a major contributor to
the MHC class I peptide pool for a number of reasons. First, it was shown to be a major
peptidase in cytosolic extracts that generated SIINFEKL from N-extended precursors.
Second, transcription of LAP is inducible by both type-I and type-II IFNs. Since IFNs
enhance MHC class I presentation and upregulate most components of this pathway, the
IFN induction of LAP suggested it might have a particularly important role during
inflammation. Third, overexpression of LAP results in a shorter half- life of peptides in
living cells (28). Given these findings , our present results are very surprising.
We have found no detectable defect in the ability of LAP-deficient mice to
generate or present MHC class I peptides , even after treatment with the type-I IFN
inducer polyI:C. In these experiments , we have measured the presentation of a number of
peptides to CTL' , including the antigenic model epitope SIINFEKL, which is a well
characterized substrate of LAP. No qualitative or quantitative difference was detected in
the priming of CTL responses to any of these epitopes in LAP-deficient mice. In
addition, we have shown in MEFs and in HeLa cells , that LAP was not required for the
trimming of peptide precursors from various N-extended SIINFEKL constructs , even in
the presence of IFNy.
One possibility is that in the absence of LAP , peptides that would normally be
trimmed into the cytosol are transported into the ER (either in their original form, or as an
intermediate precursor that has been partially trimmed by other cytosolic
aminopeptidases). ERAPI in the ER can rapidly process N-extended SIINFEKL
precursors to SIINFEKL (142), and it was possible that even if LAP deficiency led to an
increased amount ofN-extended precursors entering the ER that ERAPI activity could
mask this effect. However, although reducing ERAP 1 dramatically reduced the
presentation of SIINFEKL generated from these peptides , there was no further reduction
seen when LAP was also knocked down (Fig 12) . Therefore , ERAP1 is not masking a
contribution of LAP to trimming precursor peptides.
Although we examined a number of different peptides in this study, it is still
possible that a subset of peptides exists for which LAP is required for presentation. LAP
has been shown to hydrolyze different amino acid residues (from amino-acid-AMC
substrates) at different rates , so LAP may potentially playa more dominant role in
trimming certain sequences. However, when pep tides with different N-telminal residues
were injected into LAP-deficient HeLa cells no difference in peptide half-life was
detected, even after stimulation with IFNy. Moreover, LAP-deficient mouse cells express
normal levels ofMHC class I indicating that the overall supply of pep tides to MHC class
I is not changed. Therefore , if there are LAP-dependent epitopes , they must constitute a
minority of peptides.
Together these findings demonstrate that LAP does not play an essential role in
producing the majority of pep tides for MHC class I presentation. The fact that
SIINFEKL was presented from N-extended precursors, even in LAP + ERAPI double-
deficient cells indicates that there are other cytosolic aminopeptidases that can substitute
for LAP. Although it is possible that other aminopeptidases could be upregulated to
compensate for the absence of LAP , we have not found any consistent increase in 
PSA, and ERAPI expression that is correlated with the loss of LAP , in the MEFs (Fig 5
Although BH and PSA had slightly higher expression in LAP-KD cells (Fig 9), this may
be due to clonal variation or a difference in ~-actin expression between these two cell
lines , and is likely not responsible for the lack of an effect in these cells, particularly
under conditions ofIFNy induction since BH and PSA expression is not sensitive to IFN.
In any case , our data indicate that there must be considerable redundancy in the trimming
function of cytosolic aminopeptidases in vivo.
It is possible that the contribution of LAP to peptide supply is not apparent
because the trimming step is not rate limiting. This would explain why peptides with
one , two , or three extra residues on the N-terminus are presented with similar kinetics to
one another and to the mature epitope itself, at least in some systems (39). Under these
conditions , other aminopeptidases would be suffcient to trim antigenic precursors to
mature epitopes.
Surprisingly, we also find no evidence that LAP destroys mature epitopes , thereby
limiting their presentation. There was no increase in peptide supply in the absence of
LAP. It is possible that this is because LAP destroys as many peptides as it produces
however our data argue against such a possibility. First, LAP-deficient cells show no
defect in generating and presenting the mature SIINFEKL epitope from the ubiquitin-
SIINFEKL fusion construct, even though trimming of just one residue would generate
IINFEKL , which is too short to bind H- (Fig. 6). Second, the hydrolysis rates of
individually injected peptides are no\ different in LAP-KD cells. For these reasons, we
believe that LAP does not playa major role in the destruction of antigenic peptides under
physiological conditions. However, it should be noted that when LAP is expressed at
supraphysiologicallevels , peptides are hydrolyzed more rapidly in cells (28).
However the question remains , if LAP is not essential for antigen presentation
then why is it inducible by IFN? It is known that IFN stimulation upregulates many
components of the antigen processing pathway including the immunoproteasome.
Immunoproteasomes can generate distinct MHC class I presented peptides that are not
produced by the constitutive proteasome (189- 192). In addition, the immunoproteasome
has also been shown to generate longer peptides than the constitutive proteasome , for at
least one antigen (50) and there is indirect evidence that suggests that this might be
generally true (142). It is possible that in some cell types the immunoproteasome
generates antigenic precursors that are more effciently processed by IFN-inducible
aminopeptidases like LAP. Alternatively, it is possible that LAP is more essential in a
pathway not involved in antigen presentation such as the breakdown of some other
component involved in an immune response, or in the breakdown of viral peptides during
infection. The LAP deficient mice and cells should be useful in future studies to help
answer these questions. In addition, further investigations into the role of other cytosolic
aminopeptidases will help to define the redundancy and/or unique roles of these various
peptidases relative to LAP.
BH is not essential for the generation of MHC class I
pep tides
BH is a cytosolic cysteine protease that was thought to contribute to MHC class I
peptide presentation for two main reasons. First, it was identified along with PSA as a
major trimming activity of the VSV-NP epitope in living cells and celllysates treated
with proteasome inhibitors (60). Second, the cysteine protease inhibitor E-64 was shown
to inhibit the presentation of an MCMV epitope precursor to CTLs in combination with a
proteasome inhibitor (104).
Initially, BH was targeted by siRNA in order to determine its role in living cells.
Unfortnately, I have found that certain siRNAs can have side-effects in addition to their
ability to silence gene expression , and that these side effects can cloud any discemable
effect on MHC class I presentation. siRNA can induce type-I interferon expression by
signaling through TLR3 in a sequence independent fashion (173). By real-time PCR, one
siRNA targeting BH (BH#2) was found to induce ISG 15 to levels similar to Lucl , an
siRNA previously reported to induce IFN effects. By flow cytometry, Luc1 and BH#2
siRNAs increased overall MHC class I presentation, and reduced levels of SIINFEKL
presentation from peptide precursors. Because these phenotypes are shared between
siRNAs that do and do not reduce BH mRNA, it is diffcult to attribute them to the
reduction of BH alone. In addition, another BH siRNA targeting the 3' UTR induced
similar phenotypes that could not be rescued by overexpression of the BH open reading
frame (ORF) despite the increased levels of BH expression. This suggests that the
reduction of BH protein was not the main contributing factor to the overall increase in
MHC class I presentation, or the reduction of presentation of SIINFEKL from peptide
precursors.
Although these findings have little to do with the role of BH in antigen
presentation, it is important to notice since there are a continuously growing number of
reports that use RNAi to study intracellular and even intercellular processes that can be
affected and altered by type-I IFN. RNAi is certainly a powerful tool which can generate
good preliminary data, however it is not without its drawbacks and limitations.
With preliminary data from siRNA studies , and knowing that a BH knock-out
mouse had already been generated, we examined antigen presentation in BH-deficient
MEFs that were generated for this purpose. Overall presentation ofMHC class I was the
same in BH-deficient MEFs and control MEFs , suggesting that BH does not play an
essential role in generating the majority of peptides for MHC class I in these cells. 
addition , BH-deficient MEFs show no defect in presenting SIINFEKL from peptide
precursors containing the natural upstream sequence of SIINFEKL.
Since flanking sequences have been shown to influence presentation of particular
sequences , and because BH was specifically shown to trim the N-terminal sequence of
the VSV NP epitope , I examined the presentation of SIINFEKL when it was preceded by
the upstream sequence of the VSV -NP epitope. The lack of a defect in the presentation
of SIINFEKL from these precursors suggest that BH is not essential for trimming the
VSV NP sequence , which is not really surprising since purified PSA has also been shown
to trim this sequence (60), suggesting redundancy between these two aminopeptidases.
However, it was possible that the redundancy between BH and PSA was limited to the
trimming of a few particular sequences. In addition, one could envision a greater role for
specific aminopeptidases in specific cell types , such as professional APCs and other
immune cells.
For these reasons , BH-deficient mice were examined for their ability to present
MHC class 1. Total numbers and percentages of B-cells , CTLs , and CD4 T -cells
appeared normal in the spleen and the lymph nodes of BH -deficient mice. This suggests
that BH is not required for T-cell generation in the thymus , or maintenance in the
periphery. BH knock-out mice also have normal numbers of CD llc+ dendritic cells
which present MHC class I and MHC class II as well as wild type , suggesting that it is
not required for DC maturation, or antigen presentation by DC'
We found no defect in the ability ofBH-deficient mice to respond to a number of
viral epitopes. These viral peptides represent a wide array of sequences , therefore these
findings suggest that BH is generally not required for the trimming of specific sequences.
However, the tested viral peptides are only a small portion of a comprehensive list, and it
is possible that BH may play an essential role in generating a minor population of
peptides. Reducing presentation of a minor population of peptides may be compensated
by a reciprocal increase in presentation of peptides that are not normally presented
abundantly. Such a change would not be detectable by flow cytometry.
The ability of BH to degrade and/or trim short pep tides may be of physiological
significance, but it is clear that BH is not an essential gene. This is manifest in the
viability ofBH-deficient mice , and in the ability ofBH-deficient mice to mount a normal
immune response to viral infection from a number of viruses. Theoretically, it is possible
that BH only degrades peptides in order to recycle amino acids, but suffcient redundancy
exists to allow viability in the absence of BH which argues against an essential role for
BH in this process. Alternatively, because BH is a cytosolic aminopeptidase , it is
possible that it generates some peptides in the cytosol, but trimming activities in the ER
compensate for the loss of BH in the cytosol. If this is true , then a deficiency in BH
could be eclipsed by the function ofER-trimming activities. This speaks to the
redundancy of the system. Since aminopeptidases are present on both sides of the ER
membrane , a much clearer picture will arise when suitable reagents are available (i.
BH/ERAP 1 double-deficient mice).
PSA is not essential for the generation of MHC class I
pep tides
In this study, I show (i) that PSA does not play an indispensable role in generating
peptides presented by MHC class I , and (ii) that PSA is not essential for reproduction in
male or female mice, which contradicts previous reports (184 , 185).
PSA is a cytosolic metalloprotease that is thought to influence the MHC class I
peptide pool for a number of reasons. First, it was identified along with BH as a major
trimming activity of the VSV -NP epitope in living cells and celllysates treated with
proteasome inhibitors (60). Second, an analysis of celllysates and purified enzymes
suggested that PSA degrades the Sendai NP epitope better than any other peptidase (59).
Third, presentation of the RU1 peptide from N-extended precursors was suggested to be
dependent on PSA, in tandem with TPPII (61). Fourth, Puromycin can inhibit the
trimming of some , but not all peptides (59), indicating that PSA may preferentially
trirndegrade some peptide sequences. Together, these data implicate PSA in both
destructive and constructive processes in MHC class I peptide generation.
Because these previous studies lacked proper controls , or focused on the use of
aminopeptidase inhibitors , the role of PSA as an individual aminopeptidase in peptide
generation was stil unclear. To specifically study the role of PSA, siRNAs were
designed that target the PSA open reading frame (ORF). Two siRNAs were shown by
real-time PCR to be equally effective in reducing PSA mRNA, but resulted in very
different effects on MHC class I presentation and SIINFEKL presentation from N-
extended precursors. In contrast to BH, these phenotypic differences did not appear to be
attributable to type-I IFN effects.
In an effort to determine which of the siRNA phenotypes was correct, another
siRNA was designed which targeted the 3' UTR of endogenous PSA mRNA. This
siRNA was similar to PSA#2 in that it reduced PSA mRNA, caused an increase in overall
MHC class I , and a decrease in SIINFEKL presentation. However, these changes in
MHC class I presentation could not be attributed to PSA knockdown since
overexpression of the PSA ORF (which is not targeted by PSA-UTR) did not ameliorate
the phenotypes. Because the phenotypes are not related to the reduction of PSA, or type I
IFN effects , they must be due to other effects attributable to the siRNA sequence. It is
important to point out that PSA #1 siRNA reduced PSA mRNA, but did not affect MHC
class I or SIINFEKL presentation, which suggests that PSA is largely redundant in MHC
class I peptide generation, and correlates with my findings with PSA-deficient mice and
PSA-deficient MEFs.
But how does PSA#2 influence MHC class I presentation if not by IFN-
induction? Two main possibilities exist. First, it is possible that PSA#2 influences MHC
class I through an unknown pathway that is independent of IFN stimulation and off-target
silencing effects (discussed below). Such a pathway would be independent ofTLR3 and
PKR activation, since these ultimately lead to IFN expression. In this scenario , a protein
that binds short double-stranded RNA molecules might directly or indirectly influence
(i. e. increase) the levels of ER chaperoning, and/or protein degradation. This
hypothetical dsRNA-binding protein could act as 1) a chaperone that binds and protects
the antigenic peptides, 2) a transcription factor that increases transcription of proteins
involved in MHC class I processing, or 3) a cofactor that alters proteasome function or
TAP selectivity.
However, data presented here would indicate that the pathway that allows PSA#2
to have a different effect on MHC class I presentation would also allow a reduction in
non-homologous mRNA levels (Fig 31) . And these data would be more easily explained
by the reported the off-target silencing effects of some siRNAs. There are two possible
mechanisms for how such off- target silencing may occur. First, siRNAs can act as
microRNAs (miRNAs) by binding sequences that share less than 100% homology, and
sequestering them to prevent translation (182 , 193). Such a microRNA (miRNA)
mechanism may require as few as 8 nucleotides of homology (194).
The second mechanism by which siRNAs can mediate off-target mRNA silencing
is binding mRNAs with high, but not 100% homology, and then targeting them for
destruction. siRNAs have' been shown to target and destroy mRNAs with as many as
four mismatched nucleotides (195). The apparent promiscuity of siRNA gene-silencing
suggests that there is a much larger number of mRNA sequences that could be silenced
by any given siRNA sequence. And in reference to the work presented here , it implies
that the siRNA PSA#2 may have another (or multiple other) mRNA targets that code for
proteins directly or indirectly involved in MHC class I antigen presentation, possibly
even mRNAs encoding another protease. Such possibilities made it essential to examine
the role of PSA through a different experimental system, therefore PSA-deficient mice
were generated.
PSA-deficient MEFs were generated in order to specifically examine the
influence of PSA on antigen presentation in non-lymphoid cells. Overall MHC class 
presentation is normal in these cells , which suggests that PSA is not essential for the
generation ofMHC class I peptides. Transfection ofMEFs with a construct encoding
SIINFEKL suggested that PSA does not degrade this epitope prior to presentation. This
data is in agreement with previous work indicating that PSA does not effectively degrade
the SIINFEKL epitope (59). Microinjection ofPSA MEFs with fluorescent peptides
shows no difference in the half-life of these peptides (data not shown), which also
corroborates evidence that PSA does not contribute to the degradation of cytoplasmic
peptides.
However studies with other epitopes have suggested that PSA trims the VSV NP
epitope and epitope precursors (60), and is required for trimming some N-extended
precursors ofRUI peptide presumably due to length and sequence (61). While both
these studies demonstrate that PSA trimming activity may be redundant for some
precursors and peptides , the latter study suggests that PSA is required for the generation
ofepitopes from some peptide precursors (61).
Our studies suggest that PSA is not required for trimming peptide precursors
when they are preceded by the natural OVA sequence , or the VSV NP upstream
sequence. These findings may not be surprising since purified LAP has been shown to
trim QLESIINFEKL (53), and the VSV NP upstream sequence can be trimmed by
purified BH (60). However, these findings unambiguously extend previous work into
living cells without the use of aminopeptidase inhibitors , and suggest that there is
suffcient redundancy in the cytoplasm to trim even very long precursors (up to 16-mers)
in the absence of PSA. It also demonstrates that hydrophobic and basic residues thought
to be preferred by PSA (103) can be adequately trimmed from peptides by other
aminopeptidases in living cells. Measurements of the half-life of micro injected peptides
into BH MEFs also support these conclusions (data not shown).
All splenic cell populations were present at normal frequencies in PSA-deficient
mice. And except for DC' , all splenic lymphoid cells presented normal levels ofMHC
class 1. Both CD8+ and CD8- DC' s expressed more H- , and H- than wild type
however this increase in MHC class I presentation did not influence the activation of
CTLs in response to a variety of viral epitopes as measured by intracellular cytokine
staining.
In summary, PSA is not essential for the general trimming or degradation ofMHC
class I peptides in mice. Some data from siRNA experiments suggests that the same is
true in human cells as well.
Defining the exact amount of redundancy in aminopeptidases is necessary in
order to determine which aminopeptidases are involved in generating MHC class I
peptides in living organisms. Double knock-out mice should help in defining the level of
redundancy. Such elucidation may help in designing more effective peptide vaccines.
4.4 Other models that might be considered
Heat shock proteins are molecular chaperones expressed in eukaryotic and
prokaryotic cells that bind the hydrophobic regions of nascent proteins to aid in proper
folding (196). In addition to this role , certain groups have suggested that HSPs may bind
peptides that could serve as MHC class I peptides , thereby protecting them from
trimming and/or degradation by cytosolic aminopeptidases (197). However, exogenously
added HSP-bound peptide precursors have been shown to require proteasomal
processing, and transport into the ER by TAP in order to be presented by MHC class I
(198), suggesting that HSPs do not protect peptides from these intracellular processes.
Immunoprecipitation ofHSP70 and HSP90 followed by elution of bound peptides
indicates that antigenic peptides do not associate with these HSPs (199), and HSPs have
not been reported to specifically associate with TAP or the proteasome. These data (or
the lack thereof) argue against the idea of HSPs protectively "shuttling" peptides from the
proteasome to the TAP complex. In addition, peptides have been shown to be trimmed in
cytosolic celllysates (53) and living cells (28 , 54), which presumably include cytosolic
HSPs. These data indicate that HSPs do not protect peptides from trimming and/or
destruction by aminopeptidases in vivo.
However HSP' s are not the only proteins suggested to bind peptides in vivo. 
recent report using a modified SIINFEKL substrate (KOV AK) suggests that instead of
binding HSP' , proteolytic peptide intermediates can bind a cytosolic chaperonin TRiC
which protects them from degradation by cytosolic proteases (199). However, this repOli
does not describe an association between the TRiC complex and TAP , or TRiC and the
proteasome (199). Thus , many of the same arguments can be made against TRiC
functioning in peptide binding as in HSP' s binding peptides.
Other chaperones that reside in the ER including gp96 , calreticulin, and protein
disulfide isomerase have also been suggested to protect peptides from degradation and
increase presentation of specific epitopes (200). However, because these chaperones
reside in the ER, it is unlikely that they playa role in protecting peptides from cytosolic
proteolytic events , but possibly may sequester them and prevent them from being retro-
translocated into the cytoplasm for degradation.
Concluding remarks
The redundancy of aminopeptidases is likely to be useful to the cell in some way.
It is possible that there is so much redundancy in this system that the elimination of any
single aminopeptidase would be insignificant in reference to MHC class I antigen
processing. It is currently unknown how much of total aminopeptidase activity in cells is
attributable to each individual aminopeptidase. Such studies may be unfeasible since
expression levels of aminopeptidases vary in different cell types and under different
conditions (53). In addition , the amino acid preferences of aminopeptidases vary such
that the use of a single peptide or fluorogenic substrate may lead to an inaccurate
conclusion as to the individual contributions of various aminopeptidases to the overall
aminopeptidase acti vi ty.
The potential redundancy that may exist in aminopeptidase activity is illustrated
by a study that measured the rate of degradation of six different antigenic peptides in cell
lysates treated with a variety of aminopeptidase inhibitors. Treatment with bestatin was
shown to inhibit LAP and PSA, but this inhibition only slightly reduced the degradation
rates of six antigenic peptides (59). No reduction in peptide degradation was observed
after treatment with E-64 (a cysteine protease inhibitor) or butabindide. Together, these
data suggest that there are other aminopeptidases that can degrade these peptides.
Of equal importance is the observation that each peptide in this study was
degraded at a different rate , indicating that some sequences are more quickly degraded by
aminopeptidases than others (59). This susceptibility may be attributable to the sequence
preferences of one or more aminopeptidases.
However, the redundancy in aminopeptidases may be necessary for other cellular
processes. Aminopeptidases have recently been suggested to be required for recycling of
essential amino acids to make them available for new protein synthesis (4), and
aminopeptidase redundancy would ensure optimization of this process. It would also
prevent the build-up of pro tea somal products , which could interfere with protein-protein
interactions or be toxic in other ways. Perhaps it is for these reasons that LAP-deficient
BH-deficient, and PSA-deficient mice are viable although the dwarfism manifested by
the BH and PSA mice may suggest a role for these aminopeptidases in general growth
rates.
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and LAP-deficient animals. Amplification of the wild-tye allele results in a 800bp
fragment, whereas the disrupted allele produces a 200bp fragment. C) Western blot
analysis of celllysates prepared from Mouse Embryonic Fibroblasts (MEFs) with or
without IFNy-treatment.
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Fh!Ure 2 - MHC class I presentation in LAP-deficient and wild-type mice. FACS
analysis of A) H- (AF6-88. 5) and B) H- (KH95) expression on splenocytes 24 hrs
after intraperitoneal injection with poly I:C or with Hanks Buffered saline solution
(HBSS) as compared to staining with isotype control. Graphs represent the average
Geometric Mean Fluorescence (GMFI) of 2 mice (HBSS) or three mice (poly I:C) from
each genotype. Gray bars = C57BL/6, and white bars = LAP- . Error bars represent the
standard deviation within each group. F ACS traces represent individual mice treated
with HBSS (red = BL6, and blue = LAP- ), or with poly I:C (green = BL6, black = LAP
) and stained for A) H- , or B) H- . Data is representative of three independent
experiments.
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Fieure 3 - T-cell frequencies in wild-type and LAP-/- mice. FACS analysis ofT-cells
from lymph nodes and spleens collected from wild-type and LAP-/- mice. Graphs
represent the average % of CD8+ , B220- or CD4+, B220- cells present in each lymph
node. Five mice were used per genotype (gray bars = C57BL/6, white bars = LAP-
Error bars represent the standard deviation within each group.
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Fieure 4 - MHC classs I presentation on Mouse Embryonic Fibroblasts (MEFs). A)
MEFs, or B) MEFs treated with IFNy were analyzed by flow cytometry after staining for
with AF6 or Y3 mAbs, or for total MHC class I with the M142 mAb. Error bars
represent the average geometric mean fluorscence (GMFI) of four independent MEF
lines for each genotype. Gray bars = wild-type MEFs, and white bars = LAP-/- MEFs.
Error bars represent standard deviatiqn within each group.
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Fieure - Real-time PCR analysis of other aminopeptidases in LAP MEFs. 10 cells
were used from each of four independent MEF lines (from each genotype) to prepare
mRNA and cDNA as previously described. Results were normalized to ~-actin as
previously described. Results are representative of two independent experiments.
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Fieure 6 - SIINFEKL presentation by MEFs. 48 hours after transfection with the
indicated peptide construct, A) MEFs, or B) MEFs treated with IFNy were analyzed by
flow cytometry. F ACS traces represent gated cells expressing comparable amounts of
GFP, as shown in C). SIINFEKL presentation by H-2Kb was determined using
25.D1.16. SINFEKL presentation by two independent LAP-deficient MEFs (LAP KOI
& 2, gray line, black dotted line respectively) and wild-type MEFs (black solid line) were
compared to background staining (ct(l. gray filed line) with an isotype control antibody.
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Fieure 7 - Intracellular IFNy staining of peptide-specific T-cells. Spleen cells from LAP
/- and wild-type mice infected with virus were harvested and stimulated on, A) day 7 for
VSV, B) day 9 for LCMV, or C) day 7 for recombinant vaccinia. After isolation,
splenocytes were stimulated for five hours with anti-CD3€, as acontrol for CTL viability,
or A) VSV peptide NP52-59, B) LCMV peptides gp33, np205, gp276, and np396, or C)
vaccinia peptide pIa, or with SIINFEKL peptide as described in the materials and
methods. They were then surface stained with anti-CD8 and anti-CD44, and
intracellularly stained with anti-IFNy. Graphs and table represent the average
percentages ofCD8+ T-cells that were IFNy-positive (n=5 mice). Gray bars = C57BL/6,
white bars = LAP- . Error bars represent the standard deviation within each group.
There was no signifcant difference between LAP-/- and wild-type mice in their response
to any of the epitopes tested.
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Fieure 8 - LAP expression in the LAP-KD clone. A HeLa-Kb cell clone, stably
transfected with a shRNA construct targeting LAP (LAP-KD) was compared to control
cell lines. A) Results from real-time PCR for LAP mRNA in LAP-KD cells and control
cells with or without treatment with IFNy , all normalized to l3actin mRNA. Data is
presented as a percent of total LAP mRNA from the control cell line under constiutive
conditions (1 = 100%). Error bars represent variation between triplicate wells. B) A
western blot for LAP of LAP-KD cells and the parental cell line with or without
treatment with IFNy. Serial dilutions (1: 3) of the He La- K + IFNy cell lysate were run on
the gel in order to determine relative amounts of LAP protein between samples (lanes 5-
8). According to the semi-quantitative immunoblotting and real-time PCR, LAP-
cells have approximately 90-95% less LAP mRNA and protein, with or without IFNytreatment. 
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Fieure 9 - Real-time PCR analysis of other aminopeptidases in LAP-KD and control cell
lines. Cells stably transfected with a non-specific shRNA (Ctrl). or LAP-KD cells were
used to collect mRNA for real-time analysis as previously described. Blue bars = levels
of BH mRNA. and red = levels of PSA mRNA in both cell lines. All data is normalized
to levels of -actin. Error bars represent standard deviation between duplicate wells.
Data is representative of at least two independent experiments.
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Fhmre - Real-time PCR analysis of IFN-sensitive genes in LAP-KD and ctrl cells.
Cells stably transfected with a non-specific shRNA (Ctrl). or LAP-KD cells were used to
collect mRNA for real-time analysis as previously described. Blue bars = levels of (A)
ISG 15 or (B) PKR mRNA under constitutive growth conditions. Red bars = levels of (A)
ISG15 or (B) PKR mRNA after incubation with IFNy. All data is normalized to levels of
p-actin. Error bars represent standard deviation between duplicate wells. Data is
representative of at least two indepeJ.dent experiments.
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ure 11 - SIINFEKL presentation by LAP-KD cells. 48 hours after transfection with
the indicated peptide construct, A) LAP-KD and control cells. or B) LAP-KD and control
cells treated with IFNy were analyzed by flow cytometry. FACS traces represent gated
cells expressing comparable amounts of GFP. SIINFEKL presentation by H-2Kb was
determined using 25.D 1.16 Ab. SIINFEKL presentation by LAP-KD cells (gray line)
and control cells (black dotted line) were compared to background staining (gray filled
line) using an isotype control antibody.
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Fi!!Ure 12 - SIINFEKL presentation on shRNA-stable cells treated with ERAPI siRNA.
LAP-KD or control cells were treated with siRNA targeting ERAPI or ctrl siRNA. 
hrs later (day I), all cells were transfected with N25+SIINFEKL as previously described.
On day 3, all cells were analyzed by FACS. For the cells in B) IFNy was added on day 
FACS traces represent gated cells expressing comparable amounts of GFP. SIINFEKL
presentation by H-2Kb was determined using 25.D1.16 Ab. SIINFEKL presentation by
LAP-KD+ctrl siRNA (gray thin line), LAP-KD+ERAPI siRNA (black solid line), ctrl
cells+ctrl siRNA (black dashed line), and ctrl cells+ERAPI siRNA (gray thick line) were
all compared to cells transfected with vector and stained with 25.DI.6 (gray filed).
Although reduction of ERAPI reduced presentation of SIINFEKL, this reduction was not
enhanced or decreased by the loss of LAP, either under constitutive conditions (A), or
after 24 hrs incubation with IFNy (8).
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Fig:ure 13 - Half-life of microinjected peptides in LAP-KD cells. A) Peptides with
different residues in the PI position were microinjected into LAP-KD or control cells.
Half-life of peptide was determined by following the generation of fluorescence. B) LAP
western blot of LAP-KD and control cells after incubation with IFNy , C) peptide half-life
measured in seconds of a microinjected fluorescent peptide with leucine in the PI
position , with or without incubation with IFNy. In all these experiments, no diference in
half-life was detected in any of the tested peptides between the two cell lines.
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Fieure 14 - BH expression in HeLa-Kb cells after siRNA knock-down. HeLa-Kb cells
were transiently transfected with one of two siRNA' s targeting BH mRNA, with control
siRNA (mTOP), or untransfected (UN). A) Results from real-time PCR for BH mRNA
on day 1 or day 3 after transfection. Data is normalized to p-actin, and is presented as a
percent of total BH mRNA in cells transfected with control siRNA (mTOP). Error bars
represent variation between duplicate wells. Data is representative of at least two
independent experiments. B) A western blot for BH from soluble extracts. Extracts were
taken from cells on day 4 and day 5 after transfection with the indicated siRNA.
Previous days had similar levels. C) Serial dilutions of BH#2 and mTOP celllysates
from day 5 were run on a gel in order to determine relative amounts of BH protein.
According to semiquantitative immunoblottng and real-time PCR, BH siRNAs can
knock-down BH protein to :: 20% o,normallevels.
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ure - MHC class I expression on HeLa-Kb cells after transfection with various
siRNAs. 3 days after transfection with the indicated siRNA, HeLa-Kb cells were stained
with PA2.6 and analyzed by flow cytometry. Live cells were gated and compared. Red
line = ctrl siRNA (mTOP), blue dashed = BI--I1 siRNA, black = BH#2 siRNA. Data is
representative of at least 3 independent experiments.
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Fie:ure 16 - Real-time PCR analysis of IFN-sensitive genes in HeLa- cells treated with
siRNA. Three days after transfection with the indicated siRNA, mRNA was isolated
from HeLa- cells and used for real-time analysis as previously described. A) includes
BH#l compared to BH#2 and mTOP. B) Luc1 is compared to BH#2 and mTOP on a
different day. Blue = PKR, red = OAS, and yellow = ISG15. All data is normalized to
levels of -actin. Error bars represent standard deviation between duplicate wells. Data
is representative of at least two inde t experiments.
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ure - MHC class I presentation on HeLa- Kb cells after transfection with various
siRNAs. Two days after transfection with the indicated siRNA. HeLa-Kb cells were
stained with PA2.6 and analyzed by flow cytometry. Live cells were gated and
compared. Red line = ctrl siRNA (mTOP), blue dashed = BH#1 siRNA. black = BH#2
siRNA. yellow = Lucl. Non-specific Lucl siRNA increases MHC class I presentation
similarly to BH#2 siRNA. Data is representative of at least 3 independent experiments.
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ure SIINFEKL presentation from a peptide precursor on COS- Kb cells after
transfection with various siRNAs. 1 day after transfection with the indicated siRNA,
COS-Kb cells were transfected with a plasmid expressing a SIINFEKL peptide precursor
and GFP. On day three (post siRNA transfection), the cells were stained with 25.01.16
and analyzed by flow cytometry. Cells were gated based on comparable GFP expression.
Red line = ctrl siRNA (mTOP), black = BH#2 siRNA, yellow = Luc1. Data is
representative of at least 2 independynt experiments.
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Fieure 19 - BH expression in HeLa- cells after siRNA knockdown. HeLa-Kb cells
were transiently transfected with one of two siRNA' s targeting BH mRNA, with control
siRNA (mTOP), or with oligofectamine alone (oligo). A) Results from real-time PCR for
BH mRNA on day 1 (blue), day 2 (red), or day 3 (yellow) after transfection. Data is
normalized to -actin , and is presented as a percent of total BH mRNA in cells
transfected with control siRNA (mTOP). Error bars represent variation between
duplicate wells.
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Fi!!ure 20 - Presentation of SIINFEKL on cells treated with siRNA. A) HeLa- cells
were transfected with the indicated siRNA as previously described. 24 hrs later, all cells
were transfected with a GFP construct expressing an N2S+SIINFEKL peptide precursor.
Three days post-siRNA transfection, the cells were stained for SIINFEKL+K
presentation with 2S.D1.16. Cells were gated based on comparable GFP expression. B)
The same experiment was performed in COS- cells and analyzed as in A) with similar
results. BH-UTR reduces SIINFEK presentation as well as Luc1 and BH#2 siRNAs.
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Fieure 21 - BH siRNA effects on SIINFEKL presentation is not due to its abilty to
silence endogenous BH. COS-Kb cells were tranfected with the indicated siRNA. Then
24 hrs later, all cells were transfected with pcDNA3. N5+SIINFEKL plasmid (N-
extended precursor), and a GFP-expressing plasmid encoding BH-ORF or GFP-vector.
Three days after siRNA transfection the cells were analyzed for A) mRNA content by
real-time PCR, and B) SIINFEKL presentation. A) Real-time PCR for BH of cells that
were transfected with BH-ORF (green), or vector (blue). Data is normalized to -actin,
and is presented as a percent of total BH mRNA in cells transfected with mTOP siRNA
and vector. B) The same cells (transfected with the SIINFEKL precursor and GFP-
vector) were stained with 25.D1.l6 and analyzed for SIINFEKL presentation by FACS.
Cells were gated based on comparable GFP expression. C) Cells received BH-UTR
siRNA, N5+SIINFEKL, and either BH plasmid or vector were analyzed as in B). C)
Cells received Luc1 siRNA and the same plasm ids as in C) and were analyzed as in B).
D) Cells received mTOP ctrl siRNA and the same plasm ids as in C) and were analyzed as
in B).
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Fh!Ure 22 - MHC-class I presentation on BH-/- and wild-type MEFs. A) Mouse
embryonic fibroblasts were generated from embryos as previously described and tested
by western blot for BH expression. B) Four independent lines from each genotype were
stained for MHC class I with B8 (H- ), Y3 (H- ), or Ml42 (all and analyzed by
FACS. Bars represent the average Geometric Mean Fluorescence of the independent
MEF lines. Error bars represent the standard deviation within each group. Data is
representative of at least three indep mdent experiments.
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Fhwre 23 - SIINFEKL presentation in BH MEFs from peptide precursors. MEFs were
transfected with the indicated GFP-expressing construct and analyzed 48 hrs later. Cells
were stained with 25.D1.16 and analyzed by FACS. Gray = wild type MEFs, black =
BH-/- MEFs. Cells were gated based on GFP expression , and SIINFEKL+K
presentation was compared. Data is representative of at least three independent
experiments.
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Fil:ure 24 - MHC-class I presentation on splenocytes from BH-/- and wild type mice.
Splenocytes were stained with appropriate antibodies and analyzed by FACS. CD4+
cells were gated based on B220- , CDS- , CD4+. CDS+ cells are B220- , CD4- . B-cells are
B220+ , CD4- , CDS- . Dendritic cells (DC's) are CDllc+ , CDS6hi, and CDS+ or CDS-
Data represent 5 mice per genotype and is representative of at least three independent
experiments. Error bars represent st ndard deviation within each genotype.
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Fieure 25 - Intracellular IFNy staining of peptide-specific T -cells. Spleen cells from BH
/- and wild-type mice infected with virus were harvested and stimulated on, A) day 9 for
LCMV, B) day 7 for VSV, or C) day 7 for recombinant vaccinia. After isolation,
splenocytes were stimulated for five hours CTL responses to viral epitopes in infected
mice. BH and wild type mice were infected with A) LCMV for 9 days, B) VSV for 7
days, or C) recombinant V ac-OV A virus for 7 days. At which point, spleens were
harvested from these animals and the splenocytes were incubated with one of the
indicated peptides for 5 hours with anti-CD38 , as a control forCTL viabilty, or A)
LCMV peptides gp33, np205, gp276, and gp396, B) VSV peptide NP52-59, or C)
vaccinia peptides plO, BSR, or SIINFEKL peptides as described in the materials and
methods. They were then surface stained with anti-CDS and anti-CD44 , and
intracellularly stained with anti-IFNy. Graphs represent the avera percentages of CDS+
CD44hi T-cells that were IFNy-positive (n::5 mice). Blue bars:: wild type, and red bars
= BH- . Error bars represent the standard deviation within each group. There was no
significant difference between BH -/ - and wild type mice in their response to any of the
epitopes tested.
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Fi!!ure 26 - Half- life of microinjected pep tides in BH-/- and wild type MEFs. Peptides
with different residues in the PI position were microinjected into BH-/- or wild type
control MEFs. Half-life of peptide was determined by following the generation of
fluorescence signal. The data is expressed as A) a graph, or as B) a chart with p-values.
Statistical signifcance was determined by students t-test (two- tailed distribution
assuming equal variances). No difference in half- life was detected in any of the tested
peptides between the two cell lines. \
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Fh!Ure 27 - PSA expression in HeLa- cells after siRNA knock-down. HeLa- cells
were transiently transfected with one of two siRNAs targeting PSA mRNA, with control
siRNA (mTOP). or untransfected (UN). A) Results from real- time PCR for BH mRNA
on day 1 (blue), day 2 (red), or day 3 (yellow) after transfection. Data is normalized to 
actin, and is presented as a percent of total PSA mRNA in cells transfected with control
siRNA (mTOP). Error bars represent variation between duplicate wells. Data is
representative of at least two independent experiments. B) A western blot for PSA
overexpressed in COS- cells. COS- cells were transfected with the indicated
siRNA. 24 hours later, the same cells were transfected with PSA plasmid. 3 days post-
siRNA transfection, cytosolic extracts were taken. Western blot for PSA indicates
specific reduction ofPSA protein by PSA siRNAs. Calreticulin (CRT) was used as a
loading control.
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Fi!mre 28 - MHC class I expression on HeLa-Kb cells after transfection with various
siRNAs. 2 days after transfection with the indicated siRNA, HeLa-Kb cells were stained
with P A2.6 and analyzed by flow cytometry. Live cells were gated and compared. Red
line = ctrl siRNA (mTOP), blue line = PSA#I, green = PSA#2, and orange thick line = no
siRNA. Data is representative of at east three independent experiments.
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Fieure 29 SIINFEKL presentation from a peptide precursor on COS- cells after
transfection with various siRNAs. 1 day after transfection with the indicated siRNA,
COS- cells were transfected with a plasmid expressing a N25+SIINFEKL peptide
precursor and GFP. On day 3 (post siRNA transfection), the cells were stained with
25.D1.16 and analyzed by flow cytometry. Cells were gated based on comparable GFP
expression. Red line = ctrl siRNA (mTOP), blue = PSA#I, green = PSA#2, orange = no
siRNA, and gray are cells that did not get a SIINFEKL plasmid. Data is representative of
at least 2 independent experiments.
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Fie:ure 30 - Real-time PCR analysis of IFN-sensitive genes in HeLa- cells treated with
siRNA. Three days after transfection with the indicated siRNA, mRNA was isolated
from HeLa- cells and used for real-time analysis as previously described. Lucl and
mTOP siRNAs are compared to PSA#l and PSA#2. Blue = PKR, red = OAS, and
yellow = ISG15. All data is normalized to levels of -actin. Error bars represent
standard deviation between duplicate wells. Data is representative of at least two
independent experiments. 
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Fieure 31 - Silencing abilty of non-homologous siRNA sequences. COS- cells were
transfected with the one of two siRNAs targeting BH mRNA. with mTOP (ctrl), or with
the non-homologous PSA#2 siRNA. 24 hrs later, the same cells were transfected with a
BH plasmid. On day three post-siRNA transfection, the cells were harvested and
analyzed by A) real-time PCR for BH, or B) western blot for BH. A) and B) represent
separate experiments. C) Experiment was performed as in A) and B), except PSA#l was
used instead of BH#1. Unlike PSA#l, PSA#2 appears to silence non-homologous
mRNA sequences, which leads to a reduction of untargeted proteins.
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bmre 32 - mRNA expression in HeLa- cells after PSA siRNA knock-down. He La-
cells were transiently transfected with one of two siRNA' s targeting PSA mRNA, with
control siRNA (mTOP), or mock transfected (oligofectamine alone). A) Results from
real-time PCR for PSA mRNA on day 1 (blue), day 2 (red), or day 3 (yellow) after trans-
fection. Data is normalized to p-actin, arid is presented as a percent of total PSA mRNA
in cells transfectedwith control siRNA (mTOP). Error bars represent variation between
duplicate wells. Data is representative of at least two independent experiments. B)
mRNA from day 2 of the experiment in A) was used to determine induction of IFN-
sensitve genes by the indicated siRNAs as previously described. green = PKR, orange =
OAS, purple = ISGIS. Induction of IS GIS by PSA#2 and PSA-UTR siRNAs was
undetectable. Error bars and normalization were done as in A).
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Fhmre 33 - Presentation of SIINFEKL on cells treated with siRNAs. A) HeLa- cells
were transfected with the indicated siRNA as previously described. 24 hrs later, all cells
were transfected with a GFP construct expressing an N25+SIINFEKL peptide precursor.
Three days post-siRNA transfection, the cells were stained for SIINFEKL+K
presentation with 25.D1.16. Cells were gated based on comparable GFP expression. B)
The same experiment was performed in COS- cells and analyzed as in A) with similar
results. PSA-UTR reduces SIINFEKL presentation as well as (or more than) Luc1 and
PSA#2 siRNAs.
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Fieure 34 - PSA siRNA effects on SIINFEKL presentation is not due silencing PSA.
COS- cells were tranfected with the indicated siRNA. Then 24 hrs later, all cells were
transfected with pcDNA3. NS+SIINFEKL plasmid (N-extended precursor), and a GFP-
expressing plasmid encoding PSA-ORF or GFP-vector. Three days after siRNA
transfection the cells were analyzed for A) mRNA content by real-time PCR, and B)
SIINFEKL presentation. A) Real-time PCR for PSA of cells that were transfected with
PSA-ORF (green), or vector (blue). Data is normalized to -actin , and is presented as a
percent of total PSA mRNA in cells transfected with mTOP siRNA and vector. B) The
same cells (transfected with the SIINFEKL precursor and GFP-vector) were stained with
2S.DI.16 and analyzed for SIINFEKL presentation by FACS. Cells were gated based on
comparable GFP expression. C) Cells received PSA-UTR siRNA, NS+SIINFEKL, and
either PSA plasmid or vector were analyzed as in B). C) Cells received Luc1 siRNA and
the same plasmids as in C) and were analyzed as in B). D) Cells received mTOP ctrl
siRNA and the same plasmids as in C) and were analyzed as in B).
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Fhmre 35 - Generation of PSA-deficient mice. A) Genomic organization of the mouse
PSA gene (upper) and structure of the targeting vector (lower). Exons 1-23 are shown as
boxes with the coding regions in black. Exons 3-9 (a total of 18. 1 kb) were deleted by
homologous recombination. The active site of PSA is located in exons 9 and 10. The
locations of the primer sequences used for PCR genotype analysis are shown with arrows.
B) PCR genotype analysis of wild- type and PSA -deficient mice. Amplification of the
wild-type allele results in a 1570bp fragment, whereas the disrupted allele produced a
470bp fragment. C) Comparison of homozygote PSA-/- and +/- littermates at 4 wks of
age.
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Fh!Ure 36 - MHC class I expression on splenocytes from PSA-I- and wild type mice. A)
Splenocytes were stained with appropriate antibodies and analyzed by F ACS. CD4+
cells were gated based on B220- , CDS- , CD4+. CDS+ cells are B220- , CD4-. B-cells are
B220+ , CD4- , CDS- . Dendritic cells (DC's) are CDllc+ , CDS6hi, and CDS+ or CDS-
B) Representative FACS traces ofH-2Kb levels on CDS+ DC's from C57BL/6 (red &
orange), or PSA-I- (green & blue) mice. Students t-test was used to determine statistical
significance (* = p.:O.05). Data represent 5 wild-type mice and 3 PSA-I- mice. Data is
representative of three independent experiments. Error bars represent standard deviation
within each genotype. 
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Fi!!Ure 37 - Intracellular IFNy staining of peptide-specific T-cells. Spleen cells from
PSA-/- and wild-type mice infected with virus were harvested and stimulated on, A) day
9 for LCMV, B) day 7 for VSV, or C) day 7 for recombinant vaccinia. After isolation,
splenocytes were stimulated for five hoursCTL responses to viral epitopes in infected
mice. BH and wild type mice were infected with A) LCMV for S days, B) VSV for 7
days, C) recombinant V ac-OV A virus for 7 days, or D) Sendai virus for 6 days. At
which point, spleens were harvested from these animals and the splenocytes were
incubated with one of the indicated pep tides for S hours with anti-CD3E , as a control for
CTL viabilty, or A) LCMV peptides gp33, np20S, gp276, and gp396, B) VSV peptide
NPS2-S9, C) vaccinia peptides plO, BSR, or SIINFEKL peptide, or D) NPS2-S9 from
Sendai NP as described in the materials and methods. They were then surface stained
with anti-CDS and anti-CD44, and intracellularly stained with anti-IFNy. Graphs
represent the average percentages of CDS+ , CD44hi T-cells that were IF Ny-positive (n=S
mice). Blue bars = wild type, and red bars = PSA- . Error bars represent the standard
deviation within each group. Each graph represents at least two independent
experiments. There was no significant difference between PSA-/- and wild type mice in
their response to any of the nine epitopes tested.
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Fieure 38 - Generation and characterization ofPSA MEFs. A) MEFs were generated
from embryos as previously described and tested by real-time PCR for expression of
truncated forms of PSA mRNA. Traces above the orange line (cycle threshold) represent
PSA expression in wild-type MEFs. Traces below the line represent PSA-/- MEFs.
Thus, no truncated forms of PSA mRNA were detected. B) Four independent lines from
each genotype were stained for MHC class I with B8. 14.8S (D ), Y3 (K ), or Ml42 (all)
and analyzed by F ACS. Bars represent the average Geometric Mean Fluorescence of the
independent MEF lines. Error bars represent the standard deviation within each group.
Data is representative of at least three independent experiments.
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Fieure 39 - Aminopeptidase expression in PSA MEFs. Real-time PCR for A) LAP, B)
BH, and C) ERAPl in each of the four MEF lines from each genotype. On the right of
each graph are the four wild type MEFs. On the right are the four PSA-/- MEFs. MEFs
are presented in the same order in each graph. All data are normalized to p-actin, and are
represented as the percent of the mRNA in wild-type MEF#1. All data are representative
of two independent experiments.
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Fieure 40 - SIINFEKL presentation in PSA MEFs from peptide precursors. MEFs were
transfected with the indicated GFP-expressing construct and analyzed 48 hrs later. Cells
were stained with 25.D1.16 and analyzed by FACS. Red = wild type, blue = PSA-
MEFs. Cells were gated based on GFP expression, and SIINFEKL+K presentation was
compared. Data is representative of fit least three independent experiments.
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Fh!Ure 41 - Half-life of microinjected peptides in PSA-/- and wild type MEFs. Peptides
with different residues in the PI position were microinjected into PSA-/- or wild type
control MEFs. Half-life of peptide was determined by following the generation of
fluorescence signaL The data is expressed as A) a graph, or as B) a chart with p-values.
Statistical significance was determined by students t-test (two- tailed distribution
assuming equal variances). No difference in half-life was detected in any of the tested
peptides between the two cell lines.
Table 1- shRNA and siRNA olie:omers
Name Sequences
I LAP,hRNA . 
GM TGA TCCCA TTGCCTGTTCCTCM TCgaagcttgGGTTGAGGM T AGGCA
GTGGGf- TCA TTCTTCtttttt
. .1 gatcaaaaaaGAAGM TGA 
TCCCACTGCCT A TTCCTCMCCcaagcttcGA TTGA
GGMCAGGCM TGG  TCA TTCcg
mERAP shRNA
.1 TTCTGACACCMGMGGAGA TGACACAGgaagcttgCTGTGTCGTCTTCTTC(ctrl cell line) TTGGTGTCAGGA T AGtttttt
.lgatcaaaaaaCT A 
TCCTGACACCMGMGMGACGACACAGcaagcttcCTGTG
TCA TCTCCTTCTTGGTGTCAGMcg
1 BH#l (1058)
I GAUGGAGAGGCUGUGUGGUdTdT
I ACCACACAGCCUCUCCAUCdTdT
I BH#2 (1252)
GGAUGAUCAGGAUGGUGCUdTdT
I AGCACCAUCCUGAUCAUCCdTdT
I mTOPl
CCUCMCGAGGACACCACCdTdT
GGUGGUGUCCUCGUUGAGGdTdT
I BH-
UTR (2002) I GGUUGAUCAGAUCUGACAUdTdT
r AUGUCAGAUCUGAUCMCCdTdT
I Luc1
I GMACGAUAUGGGCUGMUACdTdT
GUAUUCAGCCCAUAUCGUU UCdTdT
I PSA#l (2320)
GCAUGGUGAUGGCACUACUdTdT
I AGUAGUGCCAUCACCAUGCdTdT
I PSA#2 (2403)
GAGUCCUUGGCGCUACUCUdTdT
I AGAGUAGCGCCMGGACUCdTdT
I PSA-
UTR (2883) CCGMCAGCUGAUUCAUAUdTdT
I AUAUGMUCAGCUGUUCGGdTdT
I Primer Name
Human 1 LAP 781 F
LAP I LAP 876R
t)-
LAP 1826R
(cloning)
Mouse I LAP BAC (F1)
LAP 
~~~
BAC
I LAP BAC (F2)
BAC
TaqMan F 
I TaqMan Rl
1 mLAP-KO (F5)
I mLAP-WT (F1)
I mLAP-WT (R1)
I mLAP-RT(F3)
mLAP-RT(R3)
Human hPSA 2049F
PSA (PSA-F3)
hPSA 2158R
(PSA-R3)
hPSA-Notl
I hPSA-KpnI2
Mouse I mPSA-WT(F3)
PSA I mPSA-KO (F1)
I mPSA-(R2)
1 mPSA-1205F
mPSA-1386R
man
;;:i
-- 
SH 787R
Table 2 - Primer SeQuences
I Sequence (5'
I gcacgccaattgatggag
I ggtctgatatggacctcg
. gaqqtacccgagccgacgagatgttc
tctaqataccatcctttgtctccgtta
AGACCCT AqAAAGGACGACGG
GGCCCTGTGACTGGCT ACTC
TGGTGCCATCTTTCTCAGGAC
GTGGTCACCTTGGTCTGCAAG
aggattgtcccaaagcctgctacgct
TGGTGTTCAGTGATGGAGGTCTAG
CATGCA
I cctctgttccacatacacttc
I gcacacttagacatagcag
I cagatatggctgattctagc
I CTTAACAGGTGCCATGGATGTAG
1 ACA TCAGCAAGCTGGCAA TC
I ctcaactctcttgtcccac
ggagtgcatcgagatgacc
ataagaattgcggccgcacactgtgggtggtgaggccttcc
gctg
I ggg atgccggagaagaggcccttcgagcgg
I gttgcataagttctgaagctgagtc
I TCA TTCTCAGT A TTGTTTTGCC
I ggagcattgaataccttccagag
I cttgttactatggaatggtgg
taggatggctgttatctaagg
ggaaqatctgatgagcagctcgggactgaattcg
ccgctcqaq tctcagccaaagctcccatggggtcc
ggaacctggtacacagtg
ggtgaatgtctctggtgg
I Notes
For real time
PCR in HeLa-
For cloning LAP-
ORF
To generate LAP
targeting
construct
(upstream)
To generate LAP
targeting
construct
(downstream)
Taqman -
screening ES
clones
For genotyping
LAP mice
For real-time
PCR in MEFs
For real-time
PCR in HeLa-
For cloning PSA-
ORF
For genotyping
PSA mice
For real-time
PCR in MEFs
For cloning SH-
ORF
For real-time
PCR in HeLa-
Mouse mBH (F)
BH I mBH (R-Vector)
1 mBH (R-WT)
I mBH-702F
1 mBH-820R
Human I h1SG15-Kpnl
ISG15 I h1SG15-Xbal
IISG-175F
ISG-319R
~~~
an 
~~~~
an 
~ ~~
Mouse mERAP1-2215F
ERAPI mERAP1-2358R
I ~-actin
B-actin F1
B-actin R1
I cactgtagctgtactcacac
I atttgtcacgtcctgcacgacg
I gcgacagagtaccatgtagg
I ggaacctggtacacagtgg
I caGGTGAAGGTCTCTGGTGG
I ggggtaccttagctccgcccgccaggctc
I tgctctagaatgggctgggacctgacggtga
I cagaagattggcgtgc
gaggttcgtcgcatttgtc
ggggtaccctaacatgtgtgtcgttcatt
tgctctagaatggctggtgatctttcagca
gctactacgtgtgagtcc
gagaccattcataagcaacg
tgctctagatcagaggatggtgcaggtccagt
ccggatccatgatggatctcagaaatacccca
ctatgtcaagctcatcgag
gcgctgcttcaggaagtc
gaggatgctcaggagccagctc
aacacagccaaggtcacatca
cgaggcccagagcaagagag
cggttggccttagggttcag
For genotyping
BH mice (161)
For real-time in
MEFs
For cloning
ISG15-0RF
For real-time
PCR in HeLa- K
For cloning PKR-
ORF
For real-time
PCR in HeLa- K
For cloning
OAS2-0RF
For real-time
PCR in HeLa- K
For real-time
- PCR in MEFs
For real-time
PCR (162)
SIINFEKL-containill! pUG plasmids
Plasmid Name Peptide Sequence
pUG 1 vector GFP only
0+S8L SIINFE
+S8L ESIINFEKL
2+S8L LESIINFEKL
S8L QLESIINFEKL
+S8L EQLESIINFEKL
+S8L LEQLESIINFEKL
VSGLEQLESIINFEKL
NPN1+S8L LSIINFEKL
NPN2+S8L DLSUNFEKL
NPN3+S8L SDLSIINFEKL
NPN4+S8L LSDLSIINFEKL
NPN5+S8L SLSDLSUNFEKL
I pIG+OV A I GFP+OV A under control 
of IRES
Table 3 - Plasmids used to transfect BH MEFs and PSA MEFs. 0+S8L thr 8+S8L
contain the natural OVA sequence of upstream ofSIINFEKL peptide. NPNI thru NPN5
contain the upstream sequence of the VSV NP peptide. pIG+OV A encodes full-length
OVA followed by an IRES and a GFP gene.
Table 4 - PSA-/- Mouse Viabilty and Fertiltv
Total Total weaned A vg. litter size Avg. PSA-
litters progeny progeny
~~~
113
PSA -/- breeders
Table 4 - PSA-/- mice are less viable as embryos and subfertile as adults. PSA+/- males
were bred with PSA+/- females , and PSA-/- males were bred with -/- females. Data
represent litter sizes at weaning (at least three weeks of age), and genotyping results
fromvweaned mice over a period of at least 7 months. Breeding pairs were housed in the
same facility, and maintained in accordance with facility protocols.
